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ABSTRACT
Cancer-related fatigue (CRF) is one of the most common and distressing symptoms in cancer 
patients and it may interfere with everyday aspects of life. Despite the recent significant increase in 
the literature on CRF it is nevertheless understudied, and several important questions involving 
experience, aetiology, assessment and interventions remain unanswered. The primary aim of this 
thesis was to advance the science of cancer-related fatigue and extend prior work by describing 
CRF over time and the relationship of fatigue to health-related quality of life in patients with 
uterine cancer who are receiving radiotherapy. Secondary aims were 1) to gain an understanding of 
the relationships between fatigue, other symptoms and selected physiological mechanisms 
associated with fatigue, and 2) to identify predictors of fatigue. The Conceptual Model of Symptom 
Management (Larson et al 1994; Dodd et al 2001) constituted the major theoretical framework for 
this dissertation. Both quantitative and qualitative methods have been used. In the qualitative study 
15 respondents were included before data saturation was achieved. The data collection and data 
analysis took place in one simultaneous process in accordance with Grounded Theory. In the 
quantitative studies 60 patients with uterine cancer who were going to receive treatment with 
radiotherapy were included. Data was collected before start of radiotherapy, during radiotherapy 
and after completed radiotherapy mainly through self-rating instruments. The quantitative data was 
analysed with descriptive and non-parametric statistical methods.
The results of the studies indicated that fatigue is an experience of the whole person. The patients 
had a low level of experienced fatigue before starting radiotherapy. The fatigue level increased 
significantly during the course of radiation therapy and after completed treatment. During the 
period of treatment, between 77 and 89% experienced fatigue. Other symptoms (loss of appetite, 
nausea/vomiting, diarrhoea, pain) also increased significantly during treatment and the increases 
were significantly correlated with general fatigue. The patients’ psychological distress (anxiety, 
depression) was low before start of treatment. Although the scores for depression had increased 
significantly after completed therapy, the levels were still within normal limits. The levels of 
coping resources, here defined as sense of coherence, were stable throughout the studies. The 
patients’ health-related quality of life was high before start of treatment. The scores for global 
quality of life and social function decreased significantly over time. There was a significant 
relationship between general fatigue and global quality of life over time when measured at baseline, 
after 3 weeks of therapy, and after completed therapy. There was also a significant correlation over 
time between general fatigue and physical function, role function and cognitive function. There was 
no significant correlation between general fatigue and EL-1, TNF-alpha or haemoglobin. There was 
a significant negative correlation between the change in IL-6 and general fatigue.
The variation in the level of general fatigue after completed therapy was explained mainly by the 
level of experienced general fatigue at baseline.
The knowledge obtained in this thesis should lead to better understanding of the cancer-related 
fatigue experience, including influencing variables, responses and outcomes, in women with 
uterine cancer who are receiving radiotherapy. Nursing interventions to help patients with CRF 
may include careful assessment, identification of patients at risk, and management of problems 
before the initiation of therapy.
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INTRODUCTION
Symptom control has today become increasingly recognized as an important 
goal in patient care (Chang (2003). Patients with cancer may experience one or 
more symptoms involving both the occurrence and the distress associated with 
the symptom. Symptom experience may be seen as the perception of the 
frequency, intensity, distress, and meaning of symptoms as they occur and are 
expressed. Symptoms are multiplicative in nature and may act as catalysts for 
the occurrence of other symptoms. Antecedents to the experience of symptoms 
may include demographic, disease, and individual factors. Consequences may 
include the impact on mood state, psychological status, functional status, 
quality of life, disease progression, and survival (Armstrong 2003).
Fatigue is one of the most frequently reported unmanaged symptoms of cancer 
patients and affects around 70-100% of all cancer patients (Ahlberg et al 2003). 
Evidence suggests that high levels of fatigue lead to significant reductions in 
physical functioning (Jacobsen et al 1999; Given et al 2001), impairment in 
quality of life (Yellen et al 1997; Cella et al 1998; Redeker et al 2000; Curt 
2000; Stone 2002), insomnia, and psychological distress (Redeker et al 2000). 
Many patients report that they cannot take part in activities as they did before, 
so they consequently lose control over parts of their life, and this can ultimately 
lead to feelings of loneliness and isolation and a further decrease in activity. 
This vicious cycle puts the patient in a distressing position (Flechtner & 
Bottomley 2003). Even cancer patients in their last period of life seem to 
experience fatigue. A study with the purpose to investigate symptom burden in 
the last week of life showed that fatigue was the most common experienced 
symptom, 83% of a sample of 270 was found to suffer from fatigue 
(Klinkenberg et al 2004).
The mechanisms responsible for the development of fatigue are poorly 
understood (Gutstein 2001) and correlations have received little attention 
(Knobel et al 2000). In a cancer setting, there may be many contributing or 
associated factors involved in the development of fatigue such as cancer itself, 
cancer treatment, depression or anxiety, some medications, pain, nausea, 
vomiting, diarrhoea, poor nutrition, anaemia, infections and insomnia (Tavio et 
al 2002).
To assess symptom experience adequately, it is essential to obtain information 
from patients about the occurrence and distress of the symptom experience 
(McDaniel & Rhodes 1995). Patients are often reluctant to report fatigue, and 
health-care professionals frequently do not screen for it because they are 
uncertain about how to treat it (Vogelzang et al 1997). Cancer patients report 
that their health-care professionals fail to recognise and adequately manage 
their fatigue (Stone et al 2000b). Health-care professionals have come to accept 
cancer-related fatigue (CRF) as expected and normal (Mock 2003). In a sample 
of 576 cancer patients, 52% had never reported their fatigue to the hospital
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doctor. There were three reasons that contributed to their not reporting fatigue: 
they thought it was inevitable (43%), unimportant (34%) or unbeatable (27%) 
(Stone et al 2000b). In order to evaluate the problem in Sweden, a 
questionnaire was mailed to 442 registered nurses in the autumn of 1995. The 
aim was to determine cancer nurses' views concerning the nature and causes of 
cancer-related fatigue and the nursing interventions, if any, they employed in 
the management of this problem. The response rate was 49%. The responses 
showed that these nurses regarded fatigue as the most common symptom in 
cancer patients, but there were few established nursing interventions. It was 
also found that nurses wanted further education and tools for evaluating 
fatigue, its causes and treatment (Magnusson et al 1997). These results were 
confirmed by Knowles and colleagues (2000), who found that while nurses 
were able to describe a number of discrete components of fatigue, they did not 
necessarily acknowledge the intensity of the symptom or assess fatigue utilising 
a specific assessment tool. The majority of nurses in that study believed further 
education in this area would be beneficial in helping them to care for these 
patients. In their study, Miller & Kearney (2001) found that knowledge and 
practice on the part of nurses was poor regarding fatigue assessment and 
management. However, the nurses demonstrated good understanding of the 
impact of fatigue on cancer patients and an appreciation of the importance of 
the nurse’s role in fatigue management. Tiesinga and colleagues (2002) 
reported that nurses, as compared with the patients themselves, are still unable 
to accurately assess a patient’s fatigue (fair agreement), exertion fatigue (fail- 
agreement) and types of fatigue (slight agreement). As a result, CRF is 
frequently underreported, underdiagnosed, and undertreated (Mock 2003). 
Even radiotherapy-induced fatigue is frequently underestimated by medical and 
nursing staff, only about 50% of patients discuss this problem with a health­
care professional, and in one fourth of the cases no intervention is proposed to 
the patient (Jereczek-Fossa et al 2002).
Uterine cancer (also termed endometrial carcinoma) is one of the most 
common cancer disease in women. Uterine cancer is more frequent after the 
reproductive years as compared with other gynaecological cancers; 96% of the 
women are 45 years or older, with a median of 64 years in women aged 50 to 
70 years, and it is often a slowly growing cancer. It can be detected early 
because it usually produces vaginal bleeding. Endometrial carcinomas 
comprise 97% of all cancers of the corpus uteri (versus uterine sarcomas, 3%) 
(Walczak 2000) and are surgically staged with a histological verification of 
grading and extent of the tumour based on guidelines from the FIGO 
committee on Gynaecological Oncology (Creasman et al 2001). Uterine cancer 
is the focus of this thesis.
In Sweden, uterine cancer is the third most common type of cancer in women, 
and approximately 1200 women receive this diagnosis each year (Cancer 
Incidence in Sweden 2001). The majority of patients are cured, but the 
treatment may induce alterations in functional status and quality of life. 
Retrospective studies have also reported high levels of psychological distress 
post-treatment (Cull et al 1993). Surgical hysterectomy is the primary treatment
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for endometrial cancer. In accordance with Swedish guidelines, the majority of 
patients are offered abdominal radiation therapy as consolidation after surgery. 
Diarrhoea and abdominal cramps are the most frequently reported side effects 
during such abdominal radiotherapy (Letschert 1995). There is still a lack of 
knowledge regarding the experience of fatigue and risk factors for developing 
fatigue in patients with uterine cancer who receive radiation therapy in a 
Swedish context.
PURPOSE
The major aim of this thesis was to obtain increased knowledge concerning 
cancer-related fatigue and extend prior work by describing fatigue over time 
and the relationship of fatigue and health-related quality of life in patients with 
uterine cancer who are receiving radiotherapy. Secondary aims were 1) to gain 
an understanding of the relationships between fatigue, other symptoms and 
selected physiological mechanisms associated with fatigue, and 2) to identify 
predictors of fatigue.
This information should lead to a better understanding of the fatigue experience 
in women with uterine cancer who are receiving radiotherapy among others and 
may contribute to the development of interventions that could be tested foi- 
future use in clinical cancer care.
CONCEPTUAL FRAMEWORK
The Conceptual Model of Symptom Management (Larson et al 1994; Dodd et 
al 2001a) was used as the major theoretical framework for this dissertation. The 
study of symptoms is based on the perception of the individual experiencing 
the symptom and his/her self report. A symptom may be defined as a subjective 
experience reflecting changes in the biopsychosocial functioning, sensations, or 
cognition of an individual. In contrast, a sign is defined as any abnormality 
indicative of disease that is detectable by the individual or by others (Dodd et al 
2001a). Symptom management is a dynamic process; it is modified by 
individual outcomes and the influences of the nursing domains of person, 
health and illness and environment (Dodd et al 2001a).
The CMSM was chosen as the theoretical framework for this thesis since it is a 
broad and extensive model that can be used for understanding symptoms, 
designing and testing management strategies, and for evaluating outcomes. 
This model was chosen instead of other related models such as the Integrated 
Fatigue Model based on the work of Piper and colleagues (1987), a model that 
mainly addresses potential causes of CRF.
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Conceptual Model of Symptom Management (CMSM)
The CMSM was developed in the School of Nursing at the University of 
California in San Francisco. The model was revised by Dodd and colleagues in 
2001, see Figure 1. The model makes it possible to study a symptom from both 
a subjective and an objective perspective. Three interrelated dimensions are 
taken into consideration: 1) symptom experience, 2) symptom management 
strategies and 3) symptom outcomes. The model is based on the relation 
between these three dimensions and the result is that a symptom can be 
mapped, evaluated and treated. Person, environment and health and illness are 
variables believed to influence all the dimensions and reflect demographic and 
biopsychosocial factors. Environment is the aggregate of conditions or 
circumstances within which a symptom occurs. Flealth and illness are 
comprised of variables including health status, disease and injury (Dodd et al 
2001b). The model does not distinguish between acute and chronic symptoms.
The symptom management model is based on six assumptions (Dodd et al 
2001a):
1) That the gold standard for the study of symptoms is based on the 
perception of the individual experiencing the symptom and his/her self 
report.
2) That the symptom does not have to be experienced by an individual in 
order to apply this model; the individual may be at risk for the 
development of the symptom because of the impact of a context 
variable such as a work hazard. Intervention strategies may be initiated 
before an individual experiences the symptom.
3) That nonverbal patients may experience symptoms, and the 
interpretation made by a caregiver, for example, is assumed to be 
accurate for purposes of intervening.
4) That all troublesome symptoms need to be managed.
5) That management strategy may target the individual, a group, a family, 
or the work environment.
6) That symptom management is a dynamic process, i.e. it is modified by 
individual outcomes and the influences of the nursing domains of 
person, health/illness, and environment.
The domains of nursing science as they relate to the CMSM
In the model, the recognised domains of nursing science, person, health/illness 
and environment, are contextual variables influencing all three dimensions of 
the model (Dodd et al 2001a).
Person domain
The person variables include demographic, psychological, sociological and 
physiological components and are intrinsic to the way an individual views and 
responds to the symptom experience.
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The health and illness domain
The health and illness domain is comprised of variables unique to the health or 
illness state of an individual and includes risk factors, injuries, or disabilities. 
Variables that are included in the health and illness domain have direct and 
indirect effects on symptom experience, management and outcomes.
Environmental domain
The environmental domain refers to the aggregate of conditions or the context 
within which a symptom occurs and includes physical, social and cultural 
variables. The physical environment may encompass home, work and hospital. 
The social environment may include the individual’s social support network 
and interpersonal relationships. Cultural aspects of the environment are those 
beliefs, values and practices that are unique to the individual’s identified 
ethnic, racial or religious group.
The symptom experience
The symptom experience includes an individual’s perception of a symptom, 
evaluation of the meaning of a symptom, and response to a symptom (Dodd et 
al 2001a).
Perception of a symptom
Perception of a symptom refers to whether an individual notices a change from 
the way he or she usually feels or behaves. For a valid self-report of symptoms, 
the person reporting must be responding to a perception of the symptom.
Evaluation of a symptom
Evaluation of the meaning of a symptom can be understood as occurring when 
people evaluate their symptoms by making judgements about the severity, 
cause, treatability and the effect of the symptoms in their lives. Evaluation of 
symptoms entails a complex set of factors that characterise the symptom 
experience, including the symptom’s intensity, location, temporal nature, 
frequency and, when appropriate, affective impact.
Response to a symptom
A person’s response to a symptom includes physiological, psychological, 
sociocultural and behavioural components. One or more of any of these 
responses may be seen with a single symptom, for example fatigue.
The outcomes of a symptom
Outcomes emerge from symptom management strategies as well as from the 
symptom experience. In the model, the outcomes dimension focuses on eight 
factors: quality of life, functional status, emotional status, mortality, morbidity 
and co-morbidity, self-care and costs. There are no arrows indicating 
directionality between the multidimensional indicators and symptom status. All 
outcomes may be related to one another as well as to symptom status (Dodd et 
al 2001a).
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Figure 1. The Revised 
Symptom Management Model 
(Larson et al 1994; Dodd et al 
2001)
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The cancer-related fatigue experience adopted from the CMSM
The focus of this thesis involved selected aspects of the experience of CRF: 
influencing variables, perception, responses, evaluation and outcomes, see 
Figure d. The symptoms management strategies dimension was not included in 
these non-intervention studies.
Figure 2. The CRF experience adopted 
from the CMSM Person
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SPECIFIC AIMS AND RESEARCH QUESTIONS
Paper 1
Specific aim:
• To explore how cancer patients experience fatigue and to describe the 
categories and dimensions of fatigue.
Research question:
• How do cancer patients experience and describe fatigue?
Paper II
Specific aim:
• To provide a comprehensive description of the experience of fatigue, 
coping resources, psychological distress, other symptoms, and health- 
related quality of life in patients with uterine cancer before start of 
radiotherapy.
Research question:
• How do patients with uterine cancer describe the experience of fatigue, 
coping resources, psychological distress, other symptoms, and health- 
related quality of life before start of radiotherapy?
Paper III
Specific aims:
• To describe over time the experience of fatigue, coping resources, 
psychological distress and functional status.
• To determine the relationships among selected variables over time in 
patients with uterine cancer who are receiving radiotherapy.
Research questions:
• How do patients with uterine cancer who are receiving radiotherapy 
describe over time the experience of fatigue, coping resources, 
psychological distress and functional status?
• What is the relationship between fatigue and coping resources, 
psychological distress and functional status?
Paper IV
Specific aims:
• To describe over time the experience of fatigue, other symptoms (loss of 
appetite, nausea/vomiting, diarrhoea, pain, insomnia) and global quality 
of life.
• To describe over time the relationship between fatigue and other 
symptoms and global quality of life in patients with uterine cancer who 
are receiving radiotherapy.
Research questions:
• How do patients with uterine cancer who are receiving radiotherapy 
describe over time the experience of fatigue, other symptoms (loss of
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appetite, nausea/vomiting, diarrhoea, pain, insomnia) and global quality 
of life?
• What is the relationship between fatigue, other symptoms and global 
quality of life?
• Which of the following baseline variables (fatigue, coping resources, 
psychological distress, other symptoms, and health-related quality of 
life) account for the greatest variance in fatigue?
Paper V
Specific aim:
• To determine the relationship between fatigue, cytokines (IL-1, IL-6, 
TNF-alpha) and haemoglobin in patients with uterine cancer who are 
receiving radiotherapy.
Research question:
• What is the relationship between fatigue, cytokines and haemoglobin 
over time in patients with uterine cancer who are receiving 
radiotherapy?
SIGNIFICANCE
Fatigue is one of the most common and distressing symptoms in patients with 
cancer, and in these patients it is a long-lasting symptom that interferes with 
everyday aspects of life (Buchsel et al 2000). Despite significant increases in 
the literature on fatigue in the recent years, fatigue remains understudied and 
several important questions are still unanswered (Winningham & Barton-Burke 
2000).
There is a lack of evidence about the experience and perception of CRF and 
correlations among selected variables over time in patients with uterine cancer 
who are receiving radiation therapy. The results obtained in this thesis can 
provide new knowledge about the experience of cancer-related fatigue, the 
relation between fatigue and other symptoms, and the outcomes of the 
symptom in a population of women with uterine cancer. The findings of this 
thesis could serve as a basis for future longitudinal studies where different 
prophylactic strategies, including nursing interventions, targeting CRF are 
prospectively studied. Furthermore, the results of this thesis will help nurses 
and other health-care professionals to better understand the fatigue experience 
in cancer patients.
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THE STATE OF KNOWLEDGE
The review of the literature concentrates on current knowledge in the area of 
interest for this thesis. The review includes scientific literature related to the 
experience of fatigue including influencing variables, perception, responses, 
evaluation and outcomes as outlined by the conceptual framework derived from 
the CMSM, see Figure 2.
Cancer-related fatigue (CRF)
Patients and health-care professionals can generally differentiate "normal" 
fatigue experienced by the general population from fatigue associated with 
cancer or its treatment. Studies have shown that healthy individuals and 
persons with a disease experience fatigue in different ways, above all with 
respect to scope, degree, and recovery (Glaus et al 1996; Cella et al 2002). 
Fatigue in patients with cancer has only recently emerged as one of the major 
concomitants of cancer and its treatment, as it has a profound impact on 
decision making, on health-related quality of life and on numerous symptoms 
(Marty & Pecorelli 2001). CRF has a clearly detrimental effect on a cancer 
patient's ability to sustain his or her usual personal, professional, and social 
relationships (Morrow et al 2002). Although most patients with cancer report 
that fatigue is a major obstacle to maintaining normal daily activities and 
quality of life, it is seldom assessed and/or treated in clinical practice (Portenoy 
& Itri 1999).
The specific mechanisms responsible for the development of CRF are not 
completely known (Andrews & Morrow 2001), but the literature indicates that 
both physiological and psychosocial factors seem to be related to the symptom 
(Ahlberg et al 2003). Proposed mechanisms include abnormalities in energy 
metabolism related to increased requirements (e.g. due to tumour growth, 
infection, fever, or surgery), decreased availability of metabolic substrates (e.g. 
due to anaemia, hypoxaemia, or poor nutrition), and the abnormal production 
of substances that impair metabolism or normal functioning of muscles (e.g. 
cytokines or antibodies). There is no clear evidence in support of any of these 
mechanisms (Portenoy & Itri 1999). Post-operative fatigue has frequently been 
observed in patients who undergo surgery as a part of their cancer treatment, 
but there is little research that has examined the causes and correlates of this 
fatigue (Stasi et al 2003). Further research aimed at identifying the mechanism 
(s) of fatigue associated with cancer and its treatment requires studies that 
characterise the phenomenon of fatigue, supplemented by measurements of a 
range of physiological and biochemical parameters (Andrews & Morrow 2001). 
In healthy individuals, physical activity has been associated with fatigue (Chen 
1986) and it may also be a cause of cancer-related fatigue (Winningham 1999). 
Fatigue is inversely correlated with activity level and with functional capacity. 
A consistent decrease in the level of daily activity over the often lengthy period
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of cancer treatment may eventually lead to a reduced tolerance for normal 
activity and high levels of fatigue (Berger & Farr 1999).
Fatigue is symptomatic of a variety of conditions in patients with cancer (Curt 
2000a). CRF occurs over a continuum, ranging from tiredness to exhaustion. 
But in contrast to “normal tiredness”, CRF is perceived as being of greater 
magnitude, disproportionate to activity or exertion, and not completely relieved 
by rest. CRF is a condition in which a person with cancer experiences an 
overwhelming and sustained sense of exhaustion and has a decreased capacity 
for physical and mental work (Glaus et al 1996). Fatigue broadly refers to a 
sense of malaise, tiredness, exhaustion, or feeling sick (Flechtner & Bottomley 
2003). There are conflicting data regarding the daily pattern of fatigue. 
According to King and others (1985), the experience of fatigue is worse in the 
afternoon. Glaus and colleagues contend that fatigue is of greater magnitude in 
the morning (Glaus 1993; Glaus et al 1996). Borthwick and colleagues (2003) 
found a clear trend indicating that patients with lung cancer who were receiving 
radiotherapy became more fatigued as the day progressed, and an indication 
that those who were more fatigued in the morning had rising levels of fatigue 
by late evening.
Only a few qualitative studies have been conducted with the aim of exploring 
the experience of fatigue from the cancer patient’s perspective (e.g. Glaus et al 
1996; Messias et al 1997). In the study by Glaus and colleagues, fatigue 
involved decreased physical performance, extreme, unusual tiredness, 
weakness and an unusual need for rest. The emerging concepts broke the 
concept of fatigue down into expressions of physical, affective and cognitive 
fatigue. The analysis by Messias and colleagues resulted in eight major 
thematic categories: (a) experiencing fatigue, (b) effects on well-being, (c) 
attribution of origin, (d) awareness and expectations, (e) emotional reactions, 
(f) activity, (g) the "biggest" concern, and (h) strategies and plans. The 
experience of cancer-related fatigue has never been investigated in a Swedish 
population using a qualitative method.
The most effective approach to symptom management is to identify the cause 
of the distressing symptom and correct it. However, in many cancer patients no 
cause for fatigue can be readily identified (Ahlberg et al 2003). The 
management of fatigue involves specific (targeting potentially reversible causes 
of fatigue) and symptomatic (targeting symptoms because no obvious aetiology 
or reversible cause for fatigue can be identified) intervention and treatment 
measures (Barnes & Bruera 2002). The management is cause-specific when 
conditions known to cause fatigue can be identified and treated (Mock et al 
2000). The effective management of CRF may involve an informed and 
supportive team of health-care professionals that assesses patients' fatigue 
levels regularly and systematically and incorporates education and counselling 
regarding strategies for coping with fatigue (Johnson 1999), and that uses 
institutional fatigue management experts for referral of patients with 
unmanaged fatigue (Mock et al 2000). Two tested interventions with consistent 
results in terms of alleviating CRF have been reported in the literature:
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treatment of cancer-related anaemia with erythropoietin agents (recombinant 
human erythropoietin and darbepotin alpha) and aerobic exercise (Ahlberg et al 
2003, Stasi et al 2003). An exercise programme that combines high- and low- 
intensity physical activities may be used to prevent and/or minimise both CRF 
as well as physical inactivity, muscle wasting and energy loss in patients 
receiving chemotherapy (Adamsen et al 2003). Almost no well-designed 
clinical trials have been conducted to evaluate pharmacological agents, with the 
exception of erythropoietin, for the treatment of CRF.
There is a lack of knowledge regarding the experience and development of 
fatigue in patients with uterine cancer who are receiving radiotherapy that 
could serve as a base for managing fatigue in the population in question.
In this thesis cancer-related fatigue is defined as a subjective and 
multidimensional experience of tiredness and/or exhaustion, persistent over 
time that varies regarding occurrence and impact on health-related quality of 
life.
Variables that may influence the experience of CRF
Person and environment
Demographic characteristics
Relationships between CRF and demographic characteristics are not well 
defined. Some socio demographics seem to be associated with fatigue. Age is 
supposed to be a risk factor for developing fatigue but there is conflicting data. 
Many conditions that would not be considered normal in a younger population 
are routinely accepted in older people as a part of so-called "normal" ageing; 
among these are many chronic and debilitating conditions such as pain, 
insomnia, weakness and fatigue (Aapro et al 2002). In a study by Schwarz and 
Hinz (2001), it was found that younger people reported better functioning and 
fewer symptoms in general compared to older. Liao & Ferrell (2000) contend 
that fatigue is a symptom often found among older people. When fatigue was 
measured with a cancer-specific fatigue instrument (MFI-20) in a healthy 
population, all subscales showed a clear and nearly linear dependence on age, 
with higher fatigue values for older persons (Schwarz et al 2003). Regarding 
gender, female patients seem to report fatigue more often than men (Tiesinga 
1999). The impact of age and gender may be of great importance in the 
interpretation of available data regarding prevalence and severity of fatigue in 
connection with cancer and cancer therapy.
A higher level of fatigue has been seen in unmarried patients with lower yearly 
income levels (Bower et al 2000). CRF has been consistently correlated with 
full time employment status (Akechi et al 1999).
Coping resources
Coping, a concept focusing on the situational context and changes within the 
context, may be simply defined as the effort to manage stress (Lazarus &
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Folkman 1984; Lazarus 1999). Coping can be viewed as adaptation, i.e. routine 
modes of getting along under relatively difficult conditions (White 1985). What 
a person experiences as stressful depends on both the characteristics of the 
environment and the characteristics of the individual.
In 1979 Antonovsky presented a theoretical model designed to advance 
understanding of the relations among stressors, coping and health (Antonovsky 
1979). This model later constituted the basis of a salutogenesis orientation 
called Sense of Coherence (SOC). The concept of SOC reflects the assumption 
that individuals have to cope with situations of distress and includes the 
following three components: comprehensibility, manageability and 
meaningfulness. Antonovsky hypothesised that the stronger the SOC, the more 
likely it is that a person will be coping successfully with life stressor situations. 
Theoretically, the SOC is assumed to be consistent in adult life (Antonovsky 
1987), and it has been empirically shown that SOC is a relatively stable 
characteristic (Langius et al 1992; Schnyder et al 2000). On the other hand, 
one’s SOC can quickly change in a negative direction, for example in 
connection with a traumatic event such as admission to a hospital (Antonovsky 
1987; Schnyder et al 2000). SOC is defined by Antonovsky (1987) as ”a global 
orientation that expresses the extent to which one has a pervasive, enduring 
though dynamic feeling of confidence that the stimuli deriving from one’s 
internal and external environments in the course of living are structured, 
predictable and explicable; the resources are available to one meet the demands 
posed by these stimuli; and these demands are challenges, worthy of 
investment and engagement”.
Risk factors for poor adjustment when afflicted with gynaecological cancer 
have not been adequately investigated (Pearman 2003). A patient’s SOC, here 
defined as coping resources, could be a factor influencing the experience of 
CRF.
Health and illness
The cancer itself
Although it seems reasonable to assume that the extent of tumour bulk or the 
presence of metastatic disease will influence the degree of fatigue, in several 
studies no correlation was found with either type of tumour or the presence of 
metastasis (Stone et al 1999; Okuyama et al 2001). This may have been 
because of the small number of patients representing each type and stage of 
disease in these studies. However, in one study of elderly patients with 
different types of newly diagnosed cancers, an effect of disease burden (early 
versus late clinical stage) on the degree of fatigue was reported (Given et al 
2001). In a study on patients with lung cancer who were receiving radiotherapy, 
higher levels of fatigue were recorded in patients with more advanced disease 
(Borthwick et al 2003). Further studies are needed to confirm these results.
Radiotherapy
Radiation therapy causes damage to both normal cells and cancer cells by 
arresting the growth rate. Acute symptoms due to the effect upon rapidly 
dividing cells (e.g. mucosal cells) develop during radiotherapy. Depending on
19
the areas involved in the radiation field, different symptoms may develop. 
Acute complications such as diarrhoea in women with uterine cancer who are 
treated with radiotherapy are usually manageable and resolve soon after 
irradiation is completed (Jereczek-Fossa 2001).
Fatigue is reported in up to 80% of patients receiving radiotherapy for lung 
cancer (Bardram et al 1996; Hickok et al 1996), prostate cancer (Stone et al 
1997; Janda et al 2000) and breast cancer (Berger 1998). In patients with rectal 
cancer who were receiving radiotherapy, higher rates of fatigue were observed 
when radiotherapy was employed in postoperative rather than preoperative 
settings (Ooi et al 1999). The incidence and severity of fatigue depend on the 
irradiated volume and involved organs (Marty et al 2001) and/or on the length 
of radiation therapy (Maher 2000) and may include other symptoms (Harrison 
et al 2001).
Fatigue usually develops during the first week of treatment and then diminishes 
two to four weeks after completed therapy. In a study by Magnan & Mood 
(2003), the onset of fatigue varied widely; patients reported fatigue onset as 
early as the first and as late as the 38th day of treatment. Several studies have 
shown that fatigue is felt to be the worst side effect during the last week of 
treatment (Peck & Boland 1977; King et al 1985; Smets et al 1998a; Fürst & 
Åhnsberg 2001). The level of fatigue slowly decreases to pre-treatment levels 
by three months after treatment (Irvine et al 1998; Schwartz et al 2000).
Anaemia
As one of several factors contributing to the development of fatigue, the 
importance of anaemia has been studied prospectively. Potential mechanisms 
include haemorrhage, haemolysis, nutritional deficiencies, and the increased 
production of cytokines, which counteract the differentiation of erythroid 
precursors, reducing the production of erythropoietin and contributing to 
impaired iron utilisation (Heinz & Fritz 1998). Anaemia is a deficiency of red 
blood cells (RBCs) or haemoglobin, which leads to a reduction in the oxygen­
carrying capacity of blood (Celia 1998). Anaemia, commonly defined as a 
haemoglobin level of <12 g/dL, occurs in over 30% of cancer patients at any 
point in time, and its incidence increases with treatment and progressive 
disease (Mercadante et al 2000). Untreated anaemia may counteract the 
efficacy of radiation therapy, and negatively affect activities of daily living, 
morbidity and mortality (Loney & Chemecky 2000), and quality ot life (Loney 
& Chemecky 2000; Celia et al 2003; Eagleton & Littlewood 2003).
It would seem reasonable to assume that the degree of anaemia correlates with 
the intensity of fatigue in cancer patients. In a study by Glaus and Muller 
(2000), haemoglobin was measured in 444 cancer patients with different types 
and stages of cancer and treatment modalities. The results of this study 
suggested that cancer patients with a haemoglobin level below llg/dl had 
higher levels of fatigue than patients with higher haemoglobin levels, 
indicating that fatigue was a function of the grade of anaemia. The correlation 
between fatigue and anaemia was most prominent with respect to physical 
fatigue such as reduced physical performance or weakness. Only prospective
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studies can define whether the degree of fatigue depends on the degree of 
anaemia or if there is simply a con-elation between the two that is dependent on 
mutual factors such as disease stage.
CRF due to anaemia has been studied frequently in connection with 
chemotherapy, but not during and after radiotherapy in patients with uterine 
cancer.
Other symptoms
Fatigue has been associated with the coexistence of other symptoms. In this 
thesis the relationship between CRF and loss of appetite, nausea/vomiting, 
pain, insomnia, and diarrhoea was further investigated. Whether there is a 
relationship between CRF and these symptoms has not been adequately 
investigated in women with uterine cancer who are receiving radiotherapy. We 
do not know if any of these symptoms can be seen as a predictor of the 
experience of CRF.
Loss of appetite
The cancer anorexia syndrome, a clinical manifestation of cachexia, is 
common, occurs in up to 80% of patients with cancer, and is one of the most 
frequent causes of death in cancer patients (Nelson 2000). Involuntary weight 
loss may be a consequence of anorexia, and correlations between fatigue and 
weight loss in patients with cancer have been documented, but there is 
conflicting data. In a study by Beach and colleagues (2001), weight loss over 
the course of treatment was significant but did not correlate with fatigue; 
fatigue did not change significantly during the measurement period. Anorexia 
has a complex pathophysiology that correlates with poor outcomes and 
compromises the patient’s quality of life. If anorexia, with ensuing malnutrition 
and weight loss, causes fatigue, efforts to maintain nutritional status can 
decrease or prevent some of the fatigue associated with cancer and its treatment 
(Kalman & Villani 1997).
Nausea/vomiting
Nausea is a subjective and unpleasant sensation that may or may not result in 
vomiting. Despite the development of efficacious pharmacological regimens, 
nausea remains a frequently reported adverse effect, especially in connection 
with anti-neoplastic therapy (Bender et al 2002). Abdominal and pelvic 
irradiation may result in nausea/vomiting (Maher 2000), which can drastically 
affect the patient’s quality of life and physical well-being (Rhodes & McDaniel 
2001). Some degree of anorexia usually accompanies nausea. As indicated 
earlier, nausea could contribute to the development of malnutrition and thus to 
the development of fatigue. Nausea may also prevent patients from getting 
enough rest (Bender et al 2002).
Diarrhoea
Diarrhoea is a symptom of major concern and a source of great discomfort for 
cancer patients. Patients with uterine cancer who receive radiation treatment 
may be afflicted with diarrhoea as a result (Maher 2000). Symptoms of acute
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radiation enteritis, predominantly diarrhoea and abdominal pain, occur in more 
than 70% of patients undergoing pelvic irradiation (Yavuz et al 2002). As 
would be expected due to the effects of radiation on the small bowel, 
Christman and colleagues (2001) found, in accordance with findings of King 
and colleagues (1985), that diarrhoea was prevalent by the second week of 
radiotherapy in patients with cervical or uterine cancer. The incidence of 
diarrhoea remained high throughout the last week of treatment. Poorly 
controlled diarrhoea may result in a range of physiological and psychological 
effects that extend beyond the patient to significant others and caregivers 
(Hogan 1998).
Pain
Pain is recognised as a personal experience and a symptom that has great 
impact on a patient's quality of life. Pain is one of the most common problems 
experienced by oncology patients. Of patients receiving active treatment, 30- 
50% experience pain on a daily basis (Allies et al 1984; Miaskowski et al 1997; 
Miaskowski & Lee 1999). Pain and fatigue have several components in 
common, such as being subjective, prevalent in most patients with cancer, and 
being caused by multiple factors of both a physical and psychological nature 
(Kaasa et al 1999). A significant positive correlation between pain and fatigue 
has been reported in cancer patients (Blesch et al 1991). Burrows and 
colleagues (1998) found in their study that patients with pain, in this case 
somatic and visceral pain, had significantly higher fatigue scores than pain-free 
patients. In addition, patients with pain had significantly more symptom 
distress, lower levels of physical and psychological well-being and total quality 
of life than pain-free patients. (Burrows et al 1998).
Insomnia
There is limited research on insomnia in patients with cancer, but evidence is 
accumulating that sleep is often disturbed in these patients, probably owing to a 
variety of causes (Ancoli-Israel et al 2001). The bulk of research on insomnia 
has been performed in general populations rather than in patients who are ill. 
Clinical experience suggests that cancer, as well as cancer treatment and 
associated symptoms, results in sleep disturbances (Dodd el al 2001b). A study 
by Berger and Farr (1999), the aim of which was to identify indicators 
involving circadian activity/rest cycles associated with higher levels of cancer- 
related fatigue (CRF), showed that women who had increased night 
awakenings reported higher CRF levels, with the strongest association being 
number of night awakenings. In a study that evaluated pain, fatigue, and sleep 
disturbances in 24 outpatients with cancer who were receiving radiation 
therapy (Miaskowski & Lee 1999), patients reported significantly lower fatigue 
scores in the morning as compared to the evening. In addition, patients 
experienced significant sleep disturbances. Patients who had received a higher 
percentage of their radiation treatments reported more sleep disturbances. 
Ancoli-Israel and colleagues (2001) reported that some degree of cancer-related 
fatigue experienced during the day may be related to sleep/wake cycles or to 
the quality and quantity of sleep obtained at night. In women with breast cancer
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who were undergoing radiotherapy, fatigue and difficulty sleeping were 
positively correlated (Mock et al 1997).
Cytokines
One possible explanation for the development of fatigue in cancer patients has 
been proposed to be the increased secretion of pro-inflammatory cytokines 
(Greenberg et al 1993; Kurzrock 2001). Pro-inflammatory cytokines, e.g. 
interleukins, interferon and tumour necrosis factor, are proteins that mediate 
cell-to-cell communication and have been reported to be released in greater 
amounts in cancer patients as part of the host response to the tumour, in 
response to tissue damage, or due to depletion of immune cell subsets 
associated with treatment for the disease (Herskind et al 1998). This cytokine 
release may contribute to the development of fatigue by affecting the endocrine 
system and neurotransmitters (Anisman et al 1996), for example, as suggested 
in chronic fatigue syndrome (Moss et al 1999). High levels of tumour necrosis 
factor (TNF-alpha), interleukin-1 (IL-1) and interleukin-6 (IL-6) have been 
described in a variety of cancers and may contribute to the experience of being 
fatigued (Kurzrock 2001). There is still a lack of knowledge regarding the 
correlation between CRF and cytokines in patients with uterine cancer who are 
receiving radiotherapy.
Evaluation of CRF
The goals of a clinical assessment of fatigue differ from the ways in which 
fatigue is measured in research, but in both approaches instruments are needed 
that are sensitive to changes in levels of fatigue (Nail 2002). Validated 
multidimensional instruments provide a more sophisticated way of assessing 
fatigue, but they are difficult to use in clinical practice because of time 
limitations and the burden on the patient. Since fatigue is primarily a 
subjectively experienced symptom, self-report measures are the most 
commonly described type of instrument for measuring fatigue in connection 
with cancer. Available self-report instruments can basically be divided into so- 
called one-dimensional or multi-dimensional instruments. The response 
formats of these instruments include yes/no, Likert-type scales, and visual 
analogue scales.
One example of a specific instrument for CRF is the revised Piper Fatigue 
Scale (PFS) (Piper et al 1998) that covers four subjective dimensions 
(cognitive, behavioural, sensory, and affective dimensions) in addition to three 
open questions regarding cause, other symptoms, and relief measures. Another 
instrument is the Functional Assessment of Cancer Therapy-Fatigue (FACT-F) 
(Yellen et al 1997). The FACT-F is designed to measure fatigue symptoms of 
cancer patients and consists of the 28 items from the FACT-General for 
assessing health-related quality of life and an additional 13 items for assessing 
fatigue. There is also an instrument that has been used mainly on patients
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receiving radiotherapy, i.e. the Multidimensional Fatigue Inventory (MFI-20) 
(Smets et al 1995; 1996). The MFI-20 is designed to cover five areas: general 
fatigue, physical fatigue, reduced activity, reduced motivation and mental 
fatigue, and consists of 20 items.
Responses to CRF
Psychological distress
Patients with cancer may experience psychological distress, e.g. anxiety and 
depression, at diagnosis, during treatment or over a long period of time as they 
adjust to life changes (Sivesind & Bade 2001). Anxiety may be defined as “an 
unpleasant subjective experience associated with the perception of real or 
imagined threat’’ (Walker 1990). While anxiety is a common psychological 
symptom in cancer patients, few patients are diagnosed or treated for the 
symptoms that can occur due to the debilitating nature of anxiety (Bottomley 
1998a). Depression is a symptom that may exist secondary to a physical illness 
and it is common in patients with different types of cancer ( Andrykowski et al
1998) . Depression may be defined as “an abnormal mood state in which a 
person characteristically has a sense of worthlessness, despair, morbid 
thoughts, and psychomotor retardation or agitation” (Thompson 1999). It is 
estimated that 20-25% of cancer patients suffer often unrecognised and 
untreated long-term depression. Symptoms can include lack of sleep, loss of 
interest in life, anxiety, imitation, loss of concentration and, in severe cases, 
thoughts of suicide, thereby leading to an overall poor quality of life 
(Bottomley 1998b). Depressive symptoms can interfere with cancer treatment, 
increase length of hospital stay, reduce ability to care for oneself, impair quality 
of life, and possibly reduce overall survival time (McDaniel et al 1995).
CRF has been consistently correlated with psychological factors such as 
anxiety and depression (Mock et al 1997; Gaston-Johansson et al 1999). A 
significant association has been shown between fatigue and anxiety (Graydon 
1994; Molassiotis et al 1996). There are conflicting data about the relationship 
between depression and fatigue, but depression seems to be prevalent in 
patients complaining of fatigue (Broeckel et al 1998; Barraclough 1999). A 
study by Tchekmedyian and colleagues (2003) examined the relationship 
between changes in depression and anxiety levels and changes in fatigue levels 
among anaemic patients with lung cancer. Improvements in fatigue were 
significantly associated with reductions in anxiety and depression. In a study 
with the aim of determining whether fatigue, depression, and pain were 
significant predictors of health status in breast cancer patients, a significant 
correlation was found between depression and fatigue (Gaston-Johansson et al
1999) . Other studies in patients receiving radiotherapy have shown that 
psychological distress is related to post-treatment fatigue (Smets et al 1998a; 
Irvine et al 1998).
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It must be remembered that fatigue is not only a symptom of many somatic 
illnesses but also one of the key symptoms of depression (Visser & Smets 
1998). The difficulty in distinguishing between fatigue and depression has been 
discussed in the literature. According to Jacobsen and colleagues (2003), 
consideration of causal mechanisms suggests why this is difficult. In addition 
to fatigue being a possible cause of depression and depression being a possible 
cause of fatigue, both fatigue and depression can share a common cause, e.g. 
both the cancer itself and cancer treatment can cause both fatigue and 
depression. These different mechanisms have implications for efforts to 
distinguish between fatigue and depression and to identify appropriate 
treatments. For example, recently developed diagnostic criteria for a clinical 
syndrome of CRF might be useful in identifying fatigue that is caused by a 
major depressive disorder for which antidepressant therapy is generally 
indicated (Jacobsen et al 2003).
Relationship between the CRF experience and outcomes
Health-related quality of life
Quality of life (QOL) is an outcome indicator that is multidimensional and 
theoretically incorporates all aspects of an individual’s life (Bowling 1995). 
Many definitions also include the notion that the patient is satisfied with his or 
her level of function in the various domains (Whalen & Fenans, 2001). The 
concept of quality of life is particularly salient for oncology nursing, since 
health-care professionals have traditionally viewed patients from a holistic 
perspective, focusing on the quality of survival. Most quality of life definitions 
are based on the World Health Organisation’s definition of health as not only 
the absence of disease or infirmity, but also a positive state of physical, mental 
and social well being (WHO 1993). When defining quality of life as it applies 
to health-care, the term “health-related” is commonly used to focus on the 
effects of illness or treatment on quality of life and to distinguish these from 
aspects beyond the realm of health-care, such as education, income and quality 
of the environment (Ferrans 2000). In this thesis, health-related quality of life is 
defined as a multidimensional experience, including various aspects of 
functioning and subjective appraisal of symptoms and well being (Muldoon et 
al 1998).
A large percentage of patients with CRF state that their fatigue affects their 
physical and psychosocial well-being and ability to work, which may lead to a 
decreased quality of life (Curt et al 2000). Likewise, pain, anxiety and 
depression have been shown to be associated with impaired quality of life 
(Smith et al 2003). Other modifying factors, e.g. physical condition, 
psychological state, coping and personality variables, may also affect the 
patient’s quality of life (Ingham & Portenoy 1996). Quality of life is dependent 
upon the interpretation and perception of the individual. As cancer patients 
become too tired to participate fully in the roles and activities that make life
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meaningful, the most important effect of cancer-related fatigue might be in the 
realm of quality of life (Ferrell et al 1996).
Functional status may be defined as the individual’s ability to meet his or her 
basic needs, fulfil his or her usual roles, and maintain health and well-being 
(Leidy 1994). Functional status is frequently discussed as a key element of 
nursing practice and a critical outcome criterion, and yet this phenomenon is 
poorly understood because terms such as functional status, functional ability, 
health status, and quality of life have been used interchangeably (Leidy 1994). 
Assessing functional status in patients with CRF can provide information about 
the individual’s functioning in routine undertakings and about the individual's 
well-being. Functional status is a significant concern for cancer patients, and 
impairment is often associated with symptoms such as fatigue (Yellen et al 
1997; Celia et al 1998; Redeker et al 2000; Curt 2000) and insomnia and 
psychological distress (Redeker et al 2000).
Until recently, treatment for gynaecological malignancies focused almost 
exclusively on prolongation of life, and few research studies adequately 
addressed issues related to health-related quality of life (Pignata et al 2001). 
The relation between fatigue and health-related quality of life over time in 
women treated with radiotherapy for gynaecological cancer has not been 
adequately investigated.
METHODS
Designs
The research designs are as follows:
Paper I: descriptive (qualitative) design.
Paper II: descriptive, correlational design.
Papers III-V: longitudinal, descriptive, correlational design.
Setting
The study took place at the Department of Oncology, Sahlgrenska University 
Hospital, where patients from both the city of Göteborg and the Western 
Region (population 1.7 million) of Sweden are referred.
Sample size
In the qualitative study (Paper I) an open sampling was used initially, but in 
order to cover the variation in the fatigue experience it became more and more 
strategic. Respondents of different ages, genders and with different medical
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diagnoses were included. Fifteen patients were interviewed before data 
saturation was achieved.
The sample in the quantitative studies (Papers II-IV) was estimated at 55 
patients at baseline according to the Wilcoxon Signed Rank test. This was 
calculated based on a statistical power of 80 % and a two-tailed probability of 
0.05, assuming the mean change in the main variable general fatigue to be 1.5 
with a SD of 3.77 (the estimations of the mean and SD were adopted from 
observations in earlier studies by Smets et al 1995; 1996) and an estimated 5% 
dropout of patients over time.
Paper V is a pilot study that will be used to develop further research questions 
and research designs (Bums & Grove 2001). Due to the high cost of 
performing cytokine measurements we decided before starting the study to 
explore the relationship between the variables of interest after 15 patients had 
been included. We estimated that with 15 patients we would be able to identity 
trends in the data.
Subjects
Paper I
The inclusion criteria for the first study were that the respondent:
• Was receiving therapy, in this case chemotherapy, as an outpatient
• Had spontaneously expressed to care staff that he or she was fatigued
• Was able to communicate about his/her experience
• Gave verbal consent to participate in the study.
Papers II-V
The inclusion criteria for the other studies were that the participants:
• Were women diagnosed with uterine cancer that, 4-6 weeks after 
surgical treatment (hysterectomy), were scheduled to receive external 
radiation therapy (46 Gy, 2 Gy/fraction, 4 days/week) as a curative 
treatment.
• Gave informed consent to participate
• Had the ability to understand, speak and read Swedish and understood 
the purpose of the study as well as the testing procedures involved.
• Were willing to have extra blood samples taken (V)
The exclusion criteria were:
• Evidence of dementia and a known history of a psychiatric disorder.
Of the 82 patients fulfilling the criteria for inclusion in Papers II-IV, 22 did not 
agree to participate. This group of 22 patients did not differ significantly from 
the study group with regard to demographic characteristics.
Concerning medications for symptoms that could influence the perception of 
fatigue, other symptoms or the patient’s quality of life, only a few patients were
27
treated for pain (n=l), insomnia (n=l) or depression (n-5). Before treatment 
started the mean Hgb value was 131 g/1. (SD=11.46).
Characteristics of the participants are presented in Tables 1 and 2.
Table 1. Demographic characteristics of the participants in Paper I
Characteristics
Paper I
N=15
Age (years)
Mean 50
Range 23-88
N %
Gender
Female 8 53
Male 7 47
Diagnosis
Lymphoma 5 33
Breast cancer 3 20
Gastrointestinal cancer 2 13
Ovarian cancer 2 13
Myeloma 1 7
Pancreatic cancer 1 7
Malignant melanoma 1 7
Treatment intention
Adj uvant/curative 8 53
Palliative 7 47
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Table 2. Demographic characteristics of the participants in Papers II-V
Characteristics
Papers II-IV
N=60
Baseline
Paper V
N=15
Baseline
Age (years)
Mean 66 64
SD 11 8
Median 64 63
Range 37-84 50-81
N % N %
Gender
Female 60 100 15 100
Marital status
Married 36 60 10 62
Single / divorced 24 40 5 38
Education
High school 42 70 9 60
Some college 4 7 1 7
College/graduate degree 14 23 5 33
Work status
Employed, full-time 8 13
Employed, half-time 6 10
Unemployed 1 2
Sick list 14 23
Retired 31 52
Children
Yes 51 85
No 9 15
Children at home 3 5
Diagnosis
Uterine cancer 60 100 15 100
Cancer stage (FIGO)
I 46 77 13 86
II 6 10 1 7
III 8 13 1 7
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The Grounded Theory method (Paper I)
Grounded Theory (GT) is a qualitative method that has been developed in the 
discipline of sociology. The aim of a GT study is to generate theoretical 
frameworks (a set of explanatory concepts) that explain the collected data. 
According to Glaser (1992), GT method is not specific to a particular discipline 
or type of data. For a long time this method is also seen as an important 
research approach for the study of nursing phenomena. GT has been used most 
frequently to study areas in which little previous research has been conducted 
and to gain a new viewpoint in familiar areas of research (Bumes & Groove 
2001). An analysis of the CRF literature, especially that concerning tools for 
measuring fatigue, suggested that there is a lack of unbiased research (Glaus 
1998). Since the experience of CRF is not yet thoroughly understood, the 
qualitative method of GT was an appropriate choice for Paper I.
Grounded Theory was originated by Glaser and Strauss in the mid to late 1960s 
(1967). With more post-positivistic underpinnings, Strauss and Corbin 
reformulated the classical version of the grounded theory in the late 1990s 
(1998). GT is based on the theoretic framework of symbolic interactionism 
(Blumer 1969). Symbolic interaction theory explores how people define reality 
and how their beliefs are related to their actions. People create reality through 
attaching meaning to situations. The meaning develops and is continuously 
modified through experience and interactions with others. The purpose of GT 
is to generate (Glaser 1978) or, as stated by Strauss and Corbin (1998), to 
develop concepts or a theory that is grounded in data. In Glaser & Strauss 
(1967), the method is described as inductive, and while in Strauss (1987) it is 
described as an inductive/deductive method. The interpretation of data is done 
on the basis of the researcher’s previous experiences and understanding, but 
with an approach to the field of research that is as unprejudiced as possible. An 
important point is that data collection and open coding occur simultaneously. In 
other words, data collection and analysis are continuous and ongoing. Once 
theoretic saturation is obtained and data collection is terminated, then the 
researcher completes the axial and selective coding.
Analysis of the interview data (Paper I)
Data analysis and data collection took place in one simultaneous process and 
continued until saturation of information was achieved, i.e. nothing new 
appeared. An open question was used at the beginning of the interview ("What 
does fatigue mean to you?”), but the rest of the interview was unstructured. The 
analysis started soon after the first interview. Each interview was transcribed 
and read through once or twice before the open coding began.
Analysis of the data was done using an approach that was influenced by the 
instructions of Strauss and Corbin (1990). In the first step, line-by-line analysis 
of the transcripts was used, substantive codes related to the content of the data 
were written in the margin, and recurrent words or sentences were underlined 
(open coding). The substantive codes were then compared with one another to
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find similarities and differences (substantive coding). The significant passages 
were extracted, marked with the number of the interview and page, and placed 
into preliminary categories. Each excerpt was then read several times and 
placed and replaced until the final categories could be determined. The 
categories were grouped until explicit categories appeared (axial coding). In the 
last step of the analysis, the categories fonned were critically reviewed and 
when necessary revised to improve the reliability of the analysis (selective 
coding). Relationships between the dimensions were sought until a concept of 
fatigue had been arrived at.
Evaluation criteria
There are some specific criteria forjudging the applicability of a GT theory: the 
theoiy must have fit and relevance and it must work. (Glaser 1978). These 
were achieved through openness, thoroughness in collecting the data, and 
consideration of all the data in the theoiy development phase. Also through that 
the data was collected until theoretic saturation was obtained. To reduce 
possible bias during the time of data collection and analysis of the data, 
frequent discussions took place between the first author and the method 
supervisor concerning the procedure for the interviews, the interviewer’s way 
of behaving towards the respondents, and the work with the analysis of the 
data.
Field notes were taken regularly during the period of the interviews. The field 
notes consisted of thoughts regarding the respondent’s expression of fatigue, 
how the respondent’s explanations fit together, and the researcher’s experience 
of the interview.
Measurements (Papers II-V)
All clinical and socio-demographic data were collected from the patients’ 
medical records. An overview of variables and methods/instruments is 
presented in Table 3.
The following instruments were used in this thesis:
Multidimensional Fatigue Inventory
Fatigue was measured using the Swedish version (Fürst & Ahnsberg 2001) of 
the Multidimensional Fatigue Inventory (MFI-20) (Smets et al 1995; Smets et 
al 1996). It consists of 20 statements which cover five dimensions of fatigue 
based on different modes of expressing fatigue: 1) General fatigue includes 
general statements concerning the person’s function such as “I feel rested”, 2) 
Physical fatigue refers to the physical sensation related to the feeling of 
tiredness. Reduction in activities and lack of motivation to start an activity are 
covered by the reduced activities and lack of motivation to start an activity 
scales in the dimensions of 3) Reduced activity and 4) Reduced motivation, 
respectively. Finally, cognitive symptoms such as having difficulties 
concentrating are included in the dimension of 5) Mental fatigue. Each
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dimension contains four items, and the dimensions are balanced to reduce the 
influence of response tendencies as much as possible; each dimension contains 
two items indicative of fatigue and two items contra-indicative of fatigue. The 
response consists of five squares ranging from agreement with the 
accompanying statement, “yes, that is true”, to disagreement, “no, that is not 
true”. The statements refer to the situation of the last few days. For each scale a 
total score is calculated by summation of the scores of the individual items, and 
scores can range from a minimum of 4 to a maximum of 20. The instrument 
can be presented as a written questionnaire to be completed in the absence of 
the researcher.
The MFI-20 has been used in several studies of cancer patients and has 
demonstrated high reliability and validity when used with patients receiving 
radiotherapy (Smets et al 1995). The Swedish version of the MFI-20 has shown 
good internal consistency (Cronbach’s alpha 0.75-0.94) (Fürst & Åhnsberg, 
2001). A reliability analysis (internal consistency) was also performed for the 
five scales in present population before the start of radiotherapy. The 
satisfactory level of Cron bach's alpha was above 0.82 for all the scales: general 
fatigue 0.89, physical fatigue 0.90, reduced activity 0.90, reduced motivation 
0.82 and mental fatigue 0.87.
Hospital Anxiety and Depression Scale
The Swedish version of the Hospital Anxiety and Depression Scale (HAD) 
(Zigmond & Snaith 1983) is a 14-item screening tool that has been used to 
measure the degree of anxiety (HADA) and depression (HADD). HAD is 
specifically developed for the detection of anxiety and depression in medically 
ill patients by excluding items related to somatic symptoms. The HAD scale 
consists of brief scales of anxiety (7 items) and depression (7 items). Responses 
concern feelings during the past week. Scores on each subscale can range 
between 0 (no symptoms of depression / anxiety) to 21 (numerous and severe 
symptoms). The scale can be used to monitor change over time. The HAD has 
been used in studies involving general medical outpatients, individuals 
experiencing chronic illnesses, e.g. cancer, and cardiac conditions, and 
nonpatient community volunteers, (Grimm 1997). HAD scores are defined as 
follows: 0-7 = non-cases, 8-10 = doubtful cases and 11-21 = cases (Zigmond & 
Snaith 1983). The internal consistency is high with a Cronbach’s alpha of 0.93 
for anxiety and 0.90 for depression (Pasacreta 1997).
Sense of Coherence Scale
Coping resources, here defined as the concept of SOC, has been 
operationalised into the Sense of Coherence Scale (Antonovsky 1987; 1993). 
The SOC scale was designed to test the hypothesis that Sense of Coherence is 
causally related to health status and that it measures overall orientation towards 
demanding life situations (Antonovsky 1987). The scale measures perceived 
comprehensibility, manageability and meaningfulness. In this study the 29-item 
version (comprehensibility 11 items, manageability 10 items, meaningfulness 8 
items) was used, and each item has a 7-point response scale. A high score on
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the scale indicates a high level of coping resources (range 29-203). Although 
the items on the three dimensions are visually separable, the SOC questionnaire 
was developed to measure the SOC as a global measure. The Swedish version 
of the SOC (29 items) has been tested and a Cronbach's alpha ranging from 
0.77 to 0.89 has been reported (Langius et al 1992; Lundman & Norberg 1993; 
Forsberg &Björvell 1996).
EORTC Quality of Life Questionnaire
The state of the art in relation to the assessment of quality of life in cancer 
patients is developmental; no measure satisfies a multidimensional model of 
quality of life (Bowling 1995). That implies that the administration of more 
than one scale is necessary in order to tap all the required dimensions.
The European Organisation for Research and Treatment of Cancer (EORTC) 
Quality of Life Questionnaire, the QLQ-C30, version 3, (Aaronson et al 1993; 
Fayers et al 1995), is a disease-specific measure covering general aspects of 
health-related quality of life. The instrument has been translated and validated 
in 38 languages, with a Cronbach's alpha coefficient 0.70 (Aaronson et al 
1993), and it has been used in more than 15000 studies worldwide (Kaasa & 
Loge 2003). The Swedish version of QLQ-C30 has been widely used and has 
demonstrated high reliability and validity in different groups of cancer patients.
The instrument consists of 30 items covering five functional scales (physical, 
role, cognitive, social, emotional function and social), three symptom scales 
(fatigue, pain and nausea/vomiting), and a global health and quality of life 
scale. Six single items are also included that measure other symptoms 
commonly reported by cancer patients (loss of appetite, insomnia, dyspnoea, 
diarrhoea, constipation, financial difficulties). Subjects are asked to rate each 
item on a four-point scale(?) (‘not at all’ to ‘very much’) with the exception of 
‘global quality of life’, which ranges from 1 (‘very poor’) to 7 (‘excellent’). 
Scores are then transformed into a 0-100 scale where a higher score represents 
a higher level of function (“better”) or a higher level of symptoms (“worse”). 
The fatigue subscale is a brief measure with three items: have you felt weak, 
did you need a rest and have you felt tired? These items are based on the 
assumption that fatigue is a side effect of the disease process. A significant 
level of reliability has been found for the fatigue subscale, with Cronbach's 
alpha of 0.80 and above, and patient acceptability of the tool is high (Bottomley 
2001).
In the quantitative studies within this thesis the instrument was used to measure 
fatigue, health-related quality of life and influencing symptoms (pain, 
nausea/vomiting, loss of appetite, insomnia, diarrhoea).
Measurement of cytokines
For cytokines measurements, peripheral venous blood samples were drawn into 
sterile blood collection tubes. The tubes were centrifuged for 20 minutes at 
3000 rpm at 4°C. The plasma samples were frozen at -70°C until the analyses 
were performed. Plasma levels of IL-1 and TNF-alpha were determined by an
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Table 3. An overview of variables and methods/instruments
Variable Method/Instrument V alidity /Reliability
INFLUENCING VARIABLES
Person Age Medical record NA
Coping resources SOC Cronbach's alpha 0.89
Environment Marital status Medical record NA
Health & illness Cancer stage Medical record NA
RT over time Medical record NA
Haemoglobin
Other symptoms:
Medical record NA
- loss of appetite
- nausea / vomiting
- diarrhoea
- pain
- insomnia
QLQ-C30 Cronbach's alpha 0.70
Cytokines
-IL-1, IL-6, TNF-alpha
Analysis of plasma NA
SYMPTOM EXPERIENCE
Perception Fatigue Grounded Theory NA
Evaluation General fatigue
Physical fatigue
Reduced activity
Reduced motivation
Mental fatigue
MFI-20 Cronbach's alpha 0.82-0.90
Fatigue as a side effect of the 
disease process
QLQ-C30 Cronbach's alpha 0.80
Responses Anxiety HAD Cronbach's alpha 0.93
Depression HAD Cronbach's alpha 0.90
OUTCOMES
Functional status QLQ-C30 Cronbach's alpha 0.70
Global quality of life QLQ-C30
ELISA procedure (M
edgenix, Fleurs, Belgium
) using recom
binant proteins to 
construct a standard curve. Plasm
a levels of ÏL-6 w
ere analysed using a 
bioassay procedure, 
using 
cell 
line 
B
 13.29, 
subclone 
B9, 
know
n 
to 
be 
dependent on IL-6 for grow
th. The analysis of all sam
ples w
as done at the sam
e 
tim
e point by the sam
e person.
Procedure
Potential subjects who met the inclusion criteria were identified by the nurses 
at the outpatient unit (I) or were consecutively identified by the project leader 
or the research nurses through the hospital’s clinical database (II-V). All 
potential participants received verbal and written information. The participants 
who were included in the studies gave their informed consent in accordance 
with the ethics committee before any data were collected.
Paper I
The interviews took place in a quiet room at the hospital and were conducted 
by the first author between May 1997 and April 1998. Each interview took 
place during a single visit. All interviews were taped and transcribed verbatim 
by the same person (first author). Fifteen patients were interviewed before data 
saturation was achieved. Demographic and clinical data (age, cancer diagnosis, 
treatment intention) were extracted from the patients’ medical records.
Papers II-IV
The data were collected within two weeks before start of radiotherapy 
(baseline), after 30 Gy (+ 3 weeks), and after completed treatment with 46 Gy 
(+5-6 weeks).
The first questionnaires (baseline) were given to the patients, instructions were 
given, and they were completed before the patients started their radiotherapy. 
Most of the subjects completed their questionnaires at the hospital. The 
remaining questionnaires (after 30 Gy and after completed therapy) were given 
directly to the patients when they visited the radiation unit or were sent to the 
patients’ homes with a pre-stamped return envelope. When a patient completed 
the questionnaire in her home she was carefully instructed about how this 
should be done and about the importance of filling it in and sending it back as 
soon as it was completed. One reminder was handed or sent out.
Demographic and clinical data (age, level of education, marital and work 
status, cancer stage, other medication, haemoglobin) were extracted from the 
patients’ medical records. The data were collected during the period 2000- 
2002.
Paper V
Fifteen patients were included in this pilot study. The data were collected 
before start of radiotherapy, after 30 Gy (+ 3 weeks) and after completed 
treatment with 46 Gy (+5-6 weeks). After receiving instructions the fatigue 
questionnaire (baseline) was completed by the patients in a private room at the 
hospital before they started radiotherapy treatment. The remaining 
questionnaires (after 30 Gy and 46 Gy) were given directly to the patients when 
they visited the radiation unit. Blood samples for the determination of 
cytokines and haemoglobin were taken when they visited the hospital, on the 
same day as the fatigue measurement. There were no missing data. All data 
were collected in 2002.
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Analysis approach (Papers II-V)
Statistical methods
Mean (m), standard deviation (sd) median (md) and range were calculated for 
descriptive purposes. All tests were two-tailed and conducted at 5% 
significance level.
Papers II-IV
For comparison over time for each variable, Friedman’s test with Tukey's post- 
hoc test were used. Spearman's correlation coefficient (denoted as r) was used 
for all correlation analyses. For correlations between two variables over time, 
intra individual correlations were calculated and formally tested with the 
Wilcoxon signed rank test. Stepwise linear regression was used, after 
transforming the dependent variable to a normal distribution by calculating 
normal scores using Blom’s method (1958), to find independent predictors 
related to change in General Fatigue and General Fatigue at baseline.
The reason a non-parametric test was chosen was that data obtained from the 
rating scales were ordered categorical responses designated as numerals. Due to 
the data distribution, the data are described as medians and ranges. However, 
since results of the MFI-20, HAD, SOC and QLQ-C30 are given as means (m) 
and standard deviations (SD) in reference studies, we also present data in that 
manner to facilitate comparisons.
Paper V
All correlations were analysed with Pitman’s nonparametric Permutation Test 
(Good 2000a). In addition, Pearson’s correlation coefficient was calculated for 
descriptive puiposes. For comparison over time, Fisher’s nonparametric 
permutation test for matched pairs (Good 2000b) was used.
Ethics
The World Medical Association’s Declaration of Helsinki (WMA 2000), 
stipulates the ethical regulations regarding research involving human research 
subjects. Ethical considerations in this study concern individual autonomy, 
informed consent, and the risk of causing emotional injury through the 
questionnaires. All data from the investigation have been treated as confidential 
information and are stored in a safe place. The studies were approved by the 
Ethics Committee at Göteborg University.
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RESULTS
The experience of fatigue in cancer patients (Paper I)
The results of the Grounded Theory study showed that the concept of fatigue 
could be understood as a process consisting of the experience of fatigue leading 
to consequences that result in actions. Three major categories were found: ( 1 ) 
experiences (of loss, need, malaise, psychological stress, emotional affection, 
abnormal weakness, difficulties in taking the initiative); (2) consequences 
(social limitation, affected self-esteem, affected quality of life); and (3) actions 
(coping activities). The categories were constructed on the basis of dimensions 
extracted from the data. The process contained a dynamic development within 
the categories.
The respondents tried to explain the experience of fatigue, but not everyone 
could find a word for it; Examples of the words used were “listless”, 
“sluggish”, “faint”, “despondent”, “apathetic”, “tired”, “slack”, “indifferent”, 
“paralysing fatigue”. The use of metaphors instead of the term fatigue was also 
common, for example “my feet feel like lead” or “I couldn’t run, my legs felt 
like spaghetti”.
The experience of fatigue and selected variables in patients with 
uterine cancer before treatment with radiotherapy (Paper II)
The second study of the patients’ experience of CRT before start of 
radiotherapy treatment showed that they experienced a low level of all 
dimensions of fatigue. The intensity levels of anxiety and depression were also 
low and defined as non-cases (0-7). The levels of other symptoms (appetite 
loss, nausea/vomiting, diarrhoea, pain, insomnia) were low and the scores for 
health-related quality of life were high.
Although the scores for fatigue mainly showed mild levels, 77% of the patients 
experienced some level of general fatigue before start of radiotherapy 
treatment. Other symptoms were also experienced to some degree: 
nausea/vomiting 22%, loss of appetite 18%, pain 37%, insomnia 55% and 
diarrhoea 15%, see Table 4.
Correlations among multiple variables (fatigue, psychological distress, coping 
resources and health-related quality of life) were analysed. Statistically 
significant correlations were found between general fatigue and anxiety 
(r=0.36, p<0.01), and between general fatigue and depression (r=0.71, 
p<0.001). The other dimensions of fatigue (mental and physical fatigue, 
reduced motivation and activity) were also found to be correlated with 
statistical significance to anxiety and depression. The correlation between 
general fatigue and coping resources was also statistically significant (r=-0.49, 
p<0.001). There was a significant negative correlation between general fatigue
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and global quality of life at baseline (r=-0.68, p<0.001). There were also 
significant negative correlations between general fatigue and the patients’ 
physical function (1--0.76, p<0.001), role function (r=-0.67, p<0.001), 
emotional function (r=-0.53, p<0.001), cognitive function (r=-0.44, p=<0.001) 
and social function (r=-0.39, p<0.01) at baseline.
A stepwise regression analysis performed before start of radiotherapy 
treatment, with anxiety, depression and coping resources as possible 
explanatory variables, resulted in a model with only depression as a significant 
explanatory variable of general fatigue. Depression explained 44% (R-square) 
of the variance in general fatigue (pcO.OOl). In addition, after adjustment for 
age, cancer stage and marital status, depression was still a significant 
independent explanatory variable for fatigue (R-Square 48%, pO.OOl).
Table 4. Prevalence of fatigue and other symptoms over time
Baseline
N=60
+30 Gy
N=47
+46 Gy
N=53
General fatigue 77% 89% 87%
Nausea/vomiting 22% 64% 44%
Loss of appetite 18% 47% 45%
Pain 37% 55% 55%
Insomnia 55% 47% 51%
Diarrhoea 15% 94% 89%
Table 5 presents means, SDs, medians and ranges of all variables of interest at 
baseline. Table 6 presents correlations between all variables.
The experience of fatigue and selected variables over time in 
patients with uterine cancer after completed treatment with 
radiotherapy (Papers III-IV)
During the first three weeks of therapy the changes from baseline were 
significant for all the fatigue dimensions (p<0.05). After completed 
radiotherapy there were significant changes over time for general fatigue, 
physical fatigue, reduced activity and reduced motivation (p<0.05), but not for
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mental fatigue. The results showed that 87% of all patients experienced some 
level of fatigue after completed treatment, see Table 4.
The participants reported normal levels of anxiety and depression that were 
defined as non-cases (0-7) during and also after completed radiotherapy, 
although the change in depression from baseline to after 3 weeks of therapy and 
after completed therapy was significant (p<0.05). The scores for sense of 
coherence did not increase significantly over time. Appetite loss, 
nausea/vomiting, diarrhoea and pain increased significantly during the first 
three weeks of therapy (p<0.05). After completed therapy the changes from 
baseline were significant for loss of appetite, nausea/vomiting and diarrhoea 
(p<0.05), but not for pain. The score for insomnia showed small changes but 
the changes were never significant. The prevalence for diarrhoea over time 
indicated that between 89-94% of all patients experienced some level of 
diarrhoea during and after completed treatment. For the prevalence for the 
other symptoms over time, see Table 4.
During the three first weeks of treatment, physical function, cognitive function 
and social function decreased, but not significantly. The opposite was seen for 
role function and emotional function, which increased. After completed therapy 
all dimensions of function had decreased, and for social function the decrease 
was significant (p<0.05). During the first three weeks of treatment the score for 
global quality of life decreased significantly (pO.05). The same significant 
decrease was seen after completed therapy (p<0.05).
The correlations over time between general fatigue and physical fatigue 
(r=0.65, pO.OOl), reduced activity (r=0.58, pO.OOl), reduced motivation 
(r=0.55, p<0.01), mental fatigue (r=0.44, p<0.05) and the fatigue subscale from 
the QLQ-C30 (r=0.79, pO.OOl) were significant. The patients’ coping 
resources did not correlate with general fatigue over time. With the exception 
of insomnia the correlation with general fatigue over time was significant for 
all symptoms: loss of appetite (r=0.72, pO.OOl), nausea/vomiting (rO.65, 
pO.OOl), diarrhoea (r=0.71, pO.OOl) and pain (rO.37, pO.Ol). The 
correlation over time between general fatigue and psychological distress was 
significant for depression (r=0.51, pO.OOl) but not for anxiety. There was a 
significant negative correlation between general fatigue and global quality of 
life after completed therapy (r=-0.57, pO.OOl). The correlation over time was 
also significant between general fatigue and physical function (r=-0.44, 
pO.OOl), role function (r=-0.48, pO.Ol), and cognitive function (r=-0.46, 
pO.Ol), but not emotional function (r=-0.10) or social function (r=-0.41).
A stepwise regression analysis, with other symptoms (loss of appetite, 
nausea/vomiting, diarrhoea, pain, insomnia) and global quality of life at 
baseline as possible explanatory variables for general fatigue at baseline, 
showed that global quality of life at baseline explained 53% (R-square) 
(pO.OOl) of the variation in general fatigue at baseline. Global quality of life 
was the only selected variable. Even after controlling for selected demographic 
factors (age, marital status and cancer stage), global quality of life was still
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significant. When anxiety, depression and functional status were investigated 
as possible explanatory variables for general fatigue, depression (p<0.01), 
physical function (p<0.01) and role function (p<0.001) explained 69% (R- 
square) of the variation in general fatigue at baseline. In addition, after 
adjustment for age, cancer stage and marital status the results were still 
significant.
When looking for predictors for the increase in the level of fatigue over time, 
with all variables as possible explanatory variables, general fatigue at baseline 
was the strongest predictor and accounted for over 50% of the variance in 
general fatigue after completed radiation therapy (R-square 53%, pO.OOl).
Table 5 presents means, SDs, medians and ranges of all variables of interest 
over time. Table 6 presents correlations between all variables of interest.
Levels of fatigue compared to levels of cytokines and haemoglobin 
during and after radiotherapy (Paper V)
The fifth and last paper, which was a pilot study, described the relationship 
between fatigue and cytokines and haemoglobin. The cytokines measured were 
IL-1, IL-6 and TNF-alpha.
The levels of IL-1 remained below the detection limit during the entire study 
period. TNF-alpha increased above the detection limit after three weeks in 5 
out of 15 patients (p=0.94), and in 4 out of 15 patients after completed therapy 
(p=0.88). The levels of IL-6 increased after 3 weeks of treatment in 7 patients 
and decreased in 8 patients (p=0.59). After completed therapy the numbers 
were the opposite; the values for 8 patients increased and for 7 they decreased 
(p=0.72). For 9 patients the level of IL-6 was higher from the beginning than 
the normal value (>85 pg/ml). Two of these patients had an increase in IL-6 
after three weeks of therapy and 6 patients after completed therapy.
Correlations between general fatigue, IL-6 and TNF-alpha were performed. 
There was a significant negative correlation between the change from baseline 
to 3 weeks of treatment (r=-0.65, p<0.01) and to end of treatment (r=-0.54, 
p<0.05) between IL-6 and general fatigue. No significant correlation was found 
between fatigue and TNF-alpha in the changes from baseline to 3 weeks of 
treatment or to end of treatment.
Haemoglobin (normal range 116-149 g/1) decreased from 137 g/1 (md) (range 
128-147) at baseline, to 131 g/1 (md) (range 118-144) after three weeks of 
therapy, and to 129 g/1 (md) (range 114-144) after completed radiotherapy. 
These changes were significant (p=<0.001). There was no significant 
correlation between changes in general fatigue and haemoglobin from baseline 
to 3 weeks of therapy (r = 0.04, p = 0.79) or to completed therapy (r=-0.18, 
p=0.23).
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Table 5: Scores for fatigue, coping resources, other symptoms, psychological distress, health-related quality of life at baseline, after 3 weeks of therapy (+30 Gy) and after 
completed therapy (+46 Gy)
Baseline
n=60 
m (SD) md (range)
After 3 weeks of therapy
n=47
m (SD) md (range)
After completed therapy 
n=53
m (SD) md (range)
Reference values 
(healthy individuals) 
m
Fatigue
General fatigue 10.4 (5.3) 9.5 (4-20) 12.7 (5.2) 12.0* (4-20) 13.1 (5.4) 14.0* (4-20) 7.8“
Physical fatigue 10.1 (5.2) 8.5 (4-20) 11.4 (5.5) 11.0* (4-20) 11.7 (5.8) 12.0* (4-20) 8.8“
Reduced activity 10.9(5.4) 11.0 (4-20) 12.2 (5.3) 12.0* (4-20) 12.6 (6.0) 13.5* (4-20) 8.4“
Reduced motivation 8.8 (4.5) 8.0 (4-20) 9.3 (5.0) 8.0* (4-20) 9.7 (5.2) 9.0* (4-20) 5.0“
Mental fatigue 8.9 (4.7) 7.5 (4-20) 9.7 (5.2) 9.0* (4-20) 9.6 (5.2) 8.5 (4-20) 5.2“
Fatigue (QLQ-C30) 30.0 (24.3) 33.3 (0-88.9) 41.2 (27.8) 33.3* (0-100) 44.6 (30.3) 44.4 (0-100) 20. lb
Coping resources (SOC)
Total Sense of Coherence 147.4(21.6) 151.0(76-179) - - 146.6(21.4) 145.0 (91-181) 151c
Other symptoms
Loss of appetite 8.9 (21.1) 0(0-100) 22.7 (29.6) 0* (0-100) 25.2 (32.6) 0*(0-100) 4.1b
Nausea / vomiting 4.4 (9.6) 0(0-50) 15.2 (15.5) 16.7* (0-66.7) 12.3 (17.9) 0* (0-83.3) 3.1b
Diarrhoea 5.6(14.0) 0 (0-66.7) 59.6 (28.6) 66.7* (0-100) 56.6 (31.1) 66.6* (0-100) 4.6b
Pain 12.5 (21.2) 0(0-83.3) 22.0 (27.8) 16.7* (0-100) 19.2 (16.7) 16.7 (0-83.3) 20.7b
Insomnia 25.6 (27.7) 33.3 (0-100) 22.0 (28.0) 0 (0-100) 26.4 (32.9) 33.0 (0-100) 22.6b
Psychological distress
Anî iety 5.4 (4.6) 4.0(0-19) 4.1 (3.6) 4.0 (0-13) 4.7 (4.4) 4.0 (0-15) -
Depression 3.4 (3.7) 2.0 (0-17) 3.8 (3.9) 2.0* (0-14) 4.2 (4.3) 2.0* (0-18) -
Glo al quality of life 75.0 (21.0) 83.3 (33.3-100) 62.2 (24.1) 66.7* (0-100) 64.0 (24.4) 66.7* (16.7-100) 77.5b
Functional status
Physical function 75.9 (21.6) 80.0 (20-100) 74.8(19.5) 80.0(33-100) 74.0 (20.3) 80.0 (33.3-100) 86.7b
Role function 64.4 (33.5) 66.7 (0-100) 66.0 (66.7) 66.7 (0-100) 62.6 (31.8) 66.7 (0-100) 86.7b
Emotional function 75.8 (20.3) 75.0(16.7-100) 80.1 (19.2) 83.3 (25-100) 78.8 (20.8) 83.3 (25-100) 83.5b
Cognitive function 86.1 (23.4) 100 (16.7-100) 84.0 (22.2) 100 (16.7-100)82.1 (21.1) 83.3 (33.3-100) 90.0b
Social function 85.0 (21.8) 100 (0-100) 77.7 (26.3) 83.3 (0-100) 72.6 (27.0) 66.7* (0-100) 92.2b
*p<0.05 Friedman's test with Tukey's post-hoc test
3 Reference values from a healthy population, women and men, aged 60-69 years, n=181 (Watt et al 2000);b Reference values from a healthy population; women, aged 60-69 
years, n=>262 (Michelson et al 2000);c Reference values from a healthy population, women and men, n=145 (Langius & Björvell 1992)
Table 6. Correlations between general fatigue and other fatigue dimensions, coping resources, selected symptoms, psychological distress and 
health-related quality of life at baseline and over time.
Baseline Over time
n=60 n=47
General fatigue General fatigue
Spearman's Rho Spearman's Rhoa
(means of intra individual correlation coefficients for all patients)
Fatigue
Physical fatigue 0.87*** 0.65***
Reduced activity 0.84 0.58***
Reduced motivation 0.68 0.55**
Mental fatigue 0.60 0.44*
Fatigue (QLQ-C-30) 0.88*** q 79***
Coping resources
Sense of Coherence _0 49*** -0.26
Other symptoms
Loss of appetite 0.44** 0.72***
Nausea/vomiting 0.28 0.65***
Diarrhoea 0.13 q 7]***
Pain 0.42 0.37**
Insomnia 0.32 0.09
Psychological distress
Anxiety 0.36** 0.08
Depression Q 7^*** 0.51***
Global quality of life -0.68*** -0 57***
Functional status
Physical function -0.76*** _0 44***
Role function -0.67*** -0.48**
Emotional function -0.53*** -0.10
Cognitive function -0 44*** -0.46**
Social function -0.39** -0.41
* p<0.05, **p<0.01, ***p<0.001
3 Formally tested with the Wilcoxon signed rank test
DISCUSSION
Symptom management is a challenging experience for health-care professionals 
including nurses. Without guidance, patients often adopt common-sense 
strategies that generally prove unsuccessful in alleviating a symptom such as 
fatigue. Within a nursing perspective, managing symptoms requires an 
understanding of the patient’s experience of the symptom as well as the 
responses and the outcomes from the symptom experience. Health-care 
professionals have difficulty developing symptom management strategies that 
can be applied across acute and home-care settings because few models of 
symptom management have been tested empirically (Dodd et al 2001a).
The Conceptual Model of Symptom Management is applicable to practice and 
to research. According to Dodd and colleagues (2001a), the model may provide 
direction for selecting clinical interventions, performing research, bridging an 
array of symptoms associated with a variety of diseases and conditions, and 
allowing for the integration of findings from other fields. Within this thesis the 
CMSM was used when designing the studies and when formulating the 
research questions for the studies. The model for the CRF experience adopted 
from the CMSM was used to get a better understanding of the complexity of 
the fatigue experience. Further, to get a deeper understanding of the results 
from the studies when looking at influencing factors, responses and outcomes 
of CRF. The model will be used and tested in further studies of CRF.
The experience and perception of fatigue in patients with cancer
The results of this thesis indicate that fatigue is an experience of the whole 
person, both body and mind. This may be compared with results in the study by 
Glaus and colleagues (1996). They showed that physical signs of fatigue were 
more frequent than affective and cognitive signs in cancer patients as compared 
with healthy individuals. The experience of fatigue involved decreased physical 
performance, extreme, unusual tiredness, weakness and an unusual need for 
rest. Affective and cognitive distress was also more prominent in cancer 
patients. The emerging concepts in their study separate fatigue into expressions 
of physical, affective and cognitive fatigue. Our results in Paper I may indicate 
that it is not possible to consider fatigue as only an experience. This means that 
if a patient describes her experience of fatigue, she is as likely to talk about a 
change in her lifestyle and her self-esteem as about how she handles the 
occurrence of the symptom. For this reason, when talking to a patient who is 
suffering from fatigue the caregiver must have an open mind in order to carry 
out an adequate assessment and documentation. In Paper I, affected self-esteem 
was found to be a consequence of fatigue. This finding has not previously been 
reported in the literature. The way in which reduced self-esteem may affect a 
person experiencing cancer-related fatigue over time needs further 
investigation.
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The dimensions of fatigue that emerged in Paper I are in good accord with 
further explanations found in the MFI-20 scales (Smets et al 1995). The scale 
concerning general fatigue corresponds to the remarks of a person concerning 
her functioning, “When my legs are tired I haven’t got any strength and then 1 
easily stagger and fall”. Physical fatigue may be expressed as “When I’m out 
walking I have to stop much more often, my feet start aching very soon”. 
Mental fatigue refers to cognitive symptoms that may be expressed as follows: 
“You can’t concentrate, when my wife asks what I’ve been reading, I don’t 
know, I can’t remember”. Reduced motivation may describe a lack of 
motivation to start any activity, which in Paper I was expressed as “I lose all 
interest and lie down instead”. Finally, the scale measuring reduced activity 
refers to consequences of fatigue that were expressed in Paper I as “I can’t get 
involved with as many things as before”.
The fact that fatigue increases during radiation therapy has been demonstrated 
in several studies in other populations (e.g. Smets et al 1996; Smets et al 1998; 
Monga et al 1999; Fürst & Åhnsberg 2001). Stone and colleagues (2001) 
reported in a study on patients with prostate cancer who were receiving 
radiotherapy with curative intent that fatigue is a significant problem for 
patients receiving radiotherapy, even though its severity is relatively modest. 
The present thesis confirms that the increase in fatigue in other populations is 
comparable to the development of fatigue in women with uterine cancer. To be 
able to define cases of fatigue there is a need for cut-off values. The increases 
of the fatigue levels can be compared to the norm data that are shown as 
reference values in Table 5. Our result shows that patients with uterine cancer 
already before the start of treatment with radiotherapy have higher levels of 
fatigue compared with a healthy population. The prevalence over time 
indicated that 87-89% of the patients experienced some level of general fatigue. 
Other researchers have found a strong association between fatigue and both 
morbidity (Appels & Mulder 1988; Avlund et al 1998; Watt el al 2000) and 
mortality (Appels & Mulder 1988; Avlund et al 1998, Fang et al 2004) in 
longitudinal studies on different cancer populations. Measures of fatigue may 
therefore be used to identify patients susceptible to future morbidity who may 
be candidates for preventive interventions.
Variables that may influence the experience of CRF
Demographic characteristics
The literature indicated that disease stage (Given et al 2001; Marty et al 2001), 
age (Liao & Ferrell 2000) and marital status (Gaston-Johansson et al 1999) may 
have an impact on the experience of fatigue. For patients with lung cancer, for 
example, the stage of cancer at diagnosis is the best predictor of symptoms in 
general later in the disease (Gift et al 2003). When controlling for age, marital 
status and disease stage in the studies within this thesis, none of the variables 
was significant regarding the development of the experience of fatigue. When 
analysing the factors influencing fatigue in a patient with cancer, distinguishing
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between demographic factors and early and/or late consequences of therapy and 
the stage of the disease itself is probably very difficult. Based on the results of 
this thesis we cannot say whether or not demographic characteristics have an 
impact on the development of fatigue. Our findings showed that demographic 
characteristics did not influence the relation between general fatigue and other 
variables. The correlation between variables did not change based on age, 
disease stage or marital status.
Coping resources and strategies
The patients’ levels of coping resources, here defined as Sense of Coherence, 
did not change significantly over time. Antonovsky contended that the SOC is 
consistent in adult life (1987) and it has been empirically shown that SOC is a 
relatively stable characteristic (Langius et al 1992; Schnyder et al 2000), which 
has been confirmed by the results of this thesis. The SOC did not change 
significantly over time. In the study by Forsberg & Björvell (1996) it was found 
that cancer patients with a strong SOC perceived their well-being as better than 
did the patients with a weaker SOC. We have not found any studies that have 
specifically looked at a possible correlation between the experience of fatigue 
and coping resources. Smets and colleagues (1998b) tested the hypothesis that 
a discrepancy between resources (e.g. optimism) and demands (e.g. the patient's 
perception of overall burden) explains most of the variance in fatigue in cancer 
patients undergoing radiotherapy. The hypothesis was not supported. In 
contrast, Servaes and colleagues (2003) found that severe fatigue at follow-up 
after treatment for malignant bone and soft tissue tumours was predicted by 
less optimism and more somatisation. Janda and colleagues (2000) reported 
that after radiotherapy for prostate carcinoma patients experienced a temporary 
deterioration in fatigue and role functioning. Despite physical deterioration, the 
authors observed an improvement in emotional functioning. The authors 
indicated that this might have been due to psychological adaptation and coping. 
A small study by Ream and colleagues (2002) was conducted to develop and 
test a nursing intervention to facilitate coping with fatigue by patients receiving 
chemotherapy. The intervention, termed the "Beating Fatigue" program, has 
four elements: assessment/monitoring, education, coaching in the management 
of fatigue, and provision of emotional support. Overall, patients were very 
positive about the program and perceived the opportunity to talk to someone 
about fatigue as the most beneficial strategy within the program.
How individuals cope with CRF may have the potential to influence their self- 
management and their experience of CRF. In the first paper within this thesis 
coping was one of the categories that was found. The respondents stated that 
they used coping strategies to deal with their fatigue, e.g. physical activity and 
planning and preparing for daily activities. Further studies are needed in order 
to find out if cancer patients use the same coping strategies over time when 
their level of fatigue is increasing and how effective these types of coping 
activities are in reducing fatigue and other symptoms.
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Others symptoms
In the papers III-IV appetite loss, nausea/vomiting and diarrhoea increased 
significantly during treatment. We also found that the increases in gastro­
intestinal (GI) symptoms were significantly correlated to the increase in general 
fatigue. These results confirm findings from other studies. A review by 
Maranzano (2001) showed that patients subjected to abdominal radiotherapy 
are at major risk for developing nausea and vomiting (71%). In studies by 
Jereczek-Fossa and colleagues (1998; 2003), 41-66 % of the patients receiving 
radiotherapy for endometrial cancer experienced bowel complications. In the 
study by King and colleagues (1985), fatigue, nausea, anorexia, and diarrhoea 
were the most frequently reported symptoms in the group of women receiving 
external radiotherapy for gynaecological cancer. The incidence of these 
symptoms increased during treatment and gradually decreased over a period of 
three months following treatment. At least 40% of the women in the study by 
Christman and colleagues (2001) reported difficulty sleeping, fatigue, 
diarrhoea, anorexia, and nausea in connection with radiation therapy for 
cervical or uterine cancer. Guren and colleagues (2003) showed in patients 
receiving radiotherapy for rectal cancer that the mean scores for diarrhoea, 
fatigue and appetite loss had significantly increased (p<0.01) at the end of 
treatment compared with pre-treatment, but this was not the case for nausea 
and pain scores. At the end of radiotherapy, diarrhoea, fatigue, appetite loss, 
physical function, social function and global quality of life were significantly 
worse than the population-based norms (Guren et al 2003).
It is important that patients with endometrial cancer who are receiving 
radiotherapy are informed of the expected changes, thereby giving them a 
chance to cope more effectively with these changes. Health-care professionals 
also need to include routines for assessment and evaluation of CRF and other 
symptoms. Because cancer patients who are receiving radiotherapy are seen 
frequently in the clinic, health-care professionals' use of a comprehensive 
approach for treating CRF and other symptoms can be of great importance.
Cytokines
The fifth paper showed that the degree of fatigue increased during radiotherapy 
without a significant change in serum levels of 1L-1, IL-6 or TNF-alpha. There 
was no significant correlation between changes in general fatigue and the 
changes in IL-1 and TNF-alpha or haemoglobin. There was a significant 
negative correlation between the change in serum IL-6 and general fatigue.
The negative correlation between changes in serum IL-6 and fatigue was 
unexpected. Although this is a very preliminary finding, the negative 
correlation between general fatigue and IL-6 could verify that fatigue is 
associated with IL-6 in the immune system.
The mechanisms for the symptom of fatigue remain to be elucidated, and other 
influencing factors also need further investigation. For instance endogenous 
cortisol was found in a study by Lundström & Fürst (2003) to have a significant 
positive correlation to fatigue, appetite loss and nausea/vomiting. The findings 
in that study supported the view of a chronic stress condition in cancer. In
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addition, the possible influence of melatonin, a product of a tryptophan 
metabolism that is cyclic and exhibits a circadian (approximately 24 hrs.) 
rhythmicity (e.g. Reppert & Weaver, 1995; Brzezinski 1997), should be further 
investigated. Melatonin affects the timing and duration of sleep. In humans, it 
increases soon after the onset of darkness, peaking in the middle of the night 
(between 0200 and 0400), and gradually decreases during the second half of the 
night.
The findings within this thesis, together with the literature, indicates that a 
comprehensive assessment, including an understanding of the most likely 
étiologie factors, is necessary for further development of a therapeutic strategy 
for CRF.
Responses to CRF
Psychological distress: anxiety and depression
The patients’ psychological distress (anxiety, depression) was low before start 
of treatment. During and also after completed radiotherapy the levels of anxiety 
and depression were still within normal limits. Depression was significantly 
correlated to general fatigue both at baseline and over time. Several studies that 
have found a positive correlation between fatigue and psychological distress, 
both in cancer patients (Smets et al 1996; Stone et al 2000a) and in healthy 
populations (Pawlikkowska et al 1994; Stone et al 2000a). The nature of the 
relationship between fatigue and anxiety and depression is complex. According 
to the literature, it is unclear whether fatigue results from prolonged emotional 
distress characterised by anxiety and depression, or whether high levels of 
fatigue cause patients to feel anxious and depressed about their reduced ability 
to take part in their usual activities. Both mechanisms seem probable (Ahlberg 
et al 2003). Dolbeault and colleagues (2001) contend that fatigue and 
depression do not follow the same clinical course and that the cause-and-effect 
relationship between these two variables has not been established (Dolbeault et 
al 2001). The same has been shown by Visser and Smets (1998), further by 
Watt with colleagues (2000). Others argue that fatigue and depression typically 
occur together in cancer patients, suggesting a common aetiology that may be 
based on serotonin. A randomised clinical trial tested whether paroxetine, a 
selective serotonin re-uptake inhibitor antidepressant known to modulate brain 
serotonin, would reduce fatigue in cancer patients and whether any reduction 
was related to depression (Morrow et al 2003). Their results showed that 
paroxetine had no influence on fatigue in patients receiving chemotherapy. A 
possible explanation is that cancer-related fatigue does not involve a reduction 
in brain 5-HT levels. Further research is needed.
47
The relationship between the fatigue experience and outcomes
In our studies the scores of functional subscales and global quality of life were 
high before start of treatment. Further, the patients’ global quality of life and 
social function decreased significantly over time. There was a significant 
relationship between general fatigue and global quality of life over time when 
measured at baseline, after 3 weeks of therapy and after completed therapy. In 
our studies as well as in the study by Smets with colleagues (1998a), the 
patients' overall quality of life was negatively related to fatigue. These results 
were also confirmed by studies on women with gynaecological cancer (e.g. 
Holzner et al 2003). A study by Curt and colleagues (2000) indicated that the 
effect of fatigue on quality of life is more profound and prolonged than the 
effects of nausea, depression or pain on quality of life. Klee and Machin (2001) 
contended that radiotherapy for endometrial cancer exposes the patients to 1-3 
months of adverse physical symptoms that impact on their daily lives. Flechtner 
and colleagues (1998) showed that the quality of life of lymphoma patients 
with high levels of fatigue remained substandard even 6-7 years after the end of 
treatment. Whether the situation is the same for patients with uterine cancer 
needs further investigation.
Predictors of fatigue
An important finding in one of our studies was that the variation in the level of 
general fatigue after completed radiotherapy was explained mainly by the level 
of experienced general fatigue at baseline. Smets and colleagues (1998) 
reported that the degree of fatigue before start of treatment might be the most 
powerful predictor of post-treatment fatigue. This means that the fatigue level 
before treatment may be an important variable when trying to find risk factors 
for the development of fatigue over the course of treatment. In a study aimed at 
identifying independent predictors of clinically significant fatigue based upon a 
multidimensional model, it was found that dyspnoea, pain, lack of appetite, 
feeling drowsy, feeling sad, and feeling irritable predicted fatigue 
independently. Physical and psychological symptoms independently predicted 
fatigue in the multidimensional model and superseded laboratory data. These 
findings support a symptom-oriented approach to assessment of CRF (Hwang 
et al 2003). Bower and colleagues (2000) found in their study of breast cancer 
survivors that depression and pain emerged as the strongest predictors of 
fatigue.
Our results concerning fatigue as its own predictor need further testing. If these 
findings are confirmed, the measurement of fatigue before treatment can be 
used as a tool to find patients at risk for developing CRF over time.
A high level of fatigue prevents patients from returning to work and from 
leading a normal life. A multidisciplinary group of practitioners, researchers, 
and patient advocates working to develop diagnosis and treatment guidelines,
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surveyed 379 patients who had undergone cancer treatment (Curt 2000a; Curt 
et al 2000b). Because of fatigue, 75% of the patients had to make changes in 
their employment status including a decrease in work hours (34%), the need to 
receive disability payments (23%), and discontinuation of work (28%). On 
average, patients reported missing almost a full week of work (4.2 days) during 
a typical month. Cancer treatment-related fatigue may result in an economic 
cost beyond lost work hours. Among respondents who experienced some level 
of fatigue, 50% reported needing help for everyday tasks such as cleaning the 
house or caring for children, which also increased monetary expenditures (Curt 
2000a; Curt et al 2000b). It is important to clarify further the differences 
between patients at high risk for this outcome and those at low risk. As the 
number of people surviving cancer for extended periods of time continues to 
increase, the phenomenon of symptoms that persist following the completion of 
treatment needs to be recognised. The development of effective interventions 
for the treatment of CRT could profoundly affect the lives of many patients 
with cancer (Manzullo et al 2003).
CONCLUSIONS
The strength of this thesis is that it addresses a symptom of significance to 
cancer patients, the experience of CRF. Further, it provides valuable evidence 
concerning the nature of fatigue in one specific patient population. The 
Symptom Management Conceptual Model has been used in this thesis as the 
framework over time, which is an innovative approach. The clinical relevance 
of this research aimed at eliminating the gaps in scientific knowledge is 
improvement in health-care professionals’ knowledge concerning the care of 
patients with uterine cancer who are receiving radiotherapy.
Our results indicate that we have confirmed existing knowledge in a new 
population of patients with cancer. We have also obtained new knowledge by 
describing fatigue, influencing variables, responses and outcomes over time 
that should lead to better understanding of cancer-related fatigue over time in 
women with uterine cancer who are receiving radiotherapy. Our findings need 
to be further investigated in other populations of cancer patients.
The results of this thesis showed that:
• Cancer-related fatigue is an experience of the whole person and that 
fatigue must be considered within the context of patients' daily lives. 
The experience of CRF may affect the patient’s self-esteem.
• Before starting radiotherapy, patients with uterine cancer have a low 
level of experienced fatigue, other symptoms and psychological distress, 
and a high level of health-related quality of life.
• Cancer-related fatigue levels increased significantly during the course of 
radiation therapy and after completed treatment.
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• Other symptoms (e.g. GI symptoms: appetite loss, nausea/vomiting and 
diarrhoea) increased significantly during treatment and the increases 
were significantly correlated to general fatigue.
• Psychological distress (anxiety and depression) remained within normal 
limits during and after completed radiotherapy.
• The patients’ levels of coping resources, here defined as Sense of 
Coherence, did not change significantly over time.
• The patients’ global quality of life and social function decreased 
significantly over time. There was a significant relationship over time 
between general fatigue and physical function, role function, cognitive 
function and global quality of life.
• There was no significant correlation between general fatigue and IL-1 
and TNF-alpha. There was a significant negative correlation between the 
change in serum IL-6 and general fatigue. There was no significant 
correlation between general fatigue and haemoglobin.
• The variation in the level of general fatigue after completed therapy was 
only explained by the level of experienced general fatigue at baseline.
METHODOLOGICAL CONSIDERATIONS
Collection of quantitative data
The use of questionnaires to collect data in paper II-V has many advantages, 
but there are also some disadvantages. A questionnaire can be difficult to 
complete and the forced choice answers may not reflect an individual’s 
experience. For practical reasons a minority of the patients in this study 
received the questionnaire by post instead of having it handed to them 
personally. This may have resulted in differences in the respondents’ 
interpretation of the different questions. To avoid bias and to reduce the lack of 
personal contact, the person who was collecting the data tried to achieve good 
contact with the participants by telephone or at the patient’s next visit at the 
hospital.
All instruments must possess two characteristics, validity and reliability. 
Concerns about reliability involve the consistency or repeatability of 
measurements made with the instrument. Cronbach's alpha is a common 
reliability test that assesses the extent to which items in an instrument are 
related. On a scale of 0 to 1.0, higher values reflect a greater degree of internal 
consistency. Validity is briefly defined as indicating whether the tool measures 
what it is claimed to measure. All questionnaires used for this project had been 
used and tested frequently. The questionnaire in this thesis that had undergone 
the least use was the Swedish version of the MFI-20. Therefore a reliability 
analysis (internal consistency) was performed, and this showed highly 
satisfactoiy Cronbach's alpha levels for all five scales.
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Response-shift
How patients evaluate their experience, in this case of fatigue, other symptoms, 
psychological distress and health-related quality of life, may changeover time. 
If patients experience extreme fatigue during treatment, they may judge the 
level of fatigue following this experience differently than they would have 
judged it before (Visser et al 2000). This paradox is now understood to reflect a 
psychological adaptation (a "response shift") that occurs in patients with cancer 
as well as in patients with other chronic diseases. The internal standard by 
which patients appraise their current state shifts and the same questionnaire 
items can elicit fundamentally different answers over time (Muldoon et al 
1998). Due to a response shift, estimates of side effects of radiotherapy may be 
attenuated if patients adapt to treatment toxicities (Jansen et al 2000). For 
example, a lower frequency of fatigue in radiotherapy patients with previous 
surgery and chemotherapy has been observed in patients with lung cancer 
(Hickok et al 1996). In the study by Visser and co-workers (2000), fatigue was 
assessed before and after radiotherapy. Following completion of the post-test 
for fatigue, a then-test was administered where patients had to provide a 
renewed judgement of their pre-treatment level of fatigue. The response shift 
was assessed by the mean difference between the pre-test and then-test scores. 
Comparing the then-test with the pre-test scores, patients retrospectively 
minimised their pre-treatment level of fatigue. The then-test - post-test 
difference was significant, whereas the conventional pre-test - post-test 
difference was not. Therefore, reported changes in selected variables need not 
necessarily derive from actual changes in health or symptoms.
Sample size in Papers II-IV
The minimum acceptable power for a study is .80 (Burnes & Groove 2001). If a 
researcher does not have sufficient power to detect differences or relationships 
that exist in the population, one might question the advisability of conducting 
the study. Large sample sizes may be difficult to obtain in studies due to the 
requirement for long data collections periods and costs (Burnes & Groove 
2001). In Papers II-IV we used the power of 80 % and two-tailed probability at 
0.05, assuming the mean change in the main variable of general fatigue to be 
1.5 with a SD of 3.77. The sample size needed was 55 patients. Our judgement 
was that the sample size would be sufficient for answering the research 
questions. The estimated 5% drop-out was a miscalculation, since we lost more 
respondents over time. Therefore the estimated sample size is not achieved 
over time, which may lead to a weaker power.
Of the 82 patients fulfilling the criteria for inclusion in Papers II-IV, 22 did not 
agree to participate. There is always a risk of missing important information 
when a cohort of the population is not included for different reasons. In a study 
like this, where the purpose was to describe patients’ experience of fatigue, it 
could be that those who were the most tired were those who declined to 
participate. Although the demographic characteristics of the patients who were 
not included in the study were similar to those of the patients in the study, we 
cannot say anything about their level of fatigue. There is always a risk of
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missing a category of patients and thereby not covering all the dimensions of a 
concept, in this case fatigue.
IMPLICATIONS FOR NURSING PRACTICE
Evidence-based health-care aims to promote effectiveness and thereby improve 
quality. The challenge for cancer nursing is to continually evaluate what it 
does, retaining effective interventions and working to develop new ones and 
refine those interventions that require improvement, thereby enhancing both 
practice and patient outcomes (Richardson et al 2002). Although CRF is a 
prevalent symptom reported by cancer patients, evaluation and management of 
this distressing side effect of cancer and cancer treatment have been limited in 
clinical practice. This limitation is related to many factors, including a lack of 
understanding of the mechanisms responsible for CRF, a lack of awareness by 
cancer-care professionals of the significance of the problem, and a lack of 
evidence-based interventions for managing CRF. Nurses play a critical role in 
maintaining and improving the well-being and health-related quality of life of 
patients at risk for developing CRF by understanding their experience and 
influencing variables and outcomes. Nurses as well as other health-care 
professionals have very limited experience with systematically using evidence- 
based knowledge in defining and managing care for the patient. Although 
specific gaps in knowledge need to be addressed in order to guide future 
practice, nurses need to use existing knowledge in the care they are delivering. 
Adoption of evidence-based practice requires ongoing education of nurses and 
support from nursing colleagues, nursing researchers, nursing administration, 
and associated health-care professionals.
Assessment is one key to the recognition and management of cancer-related 
fatigue. The use of simple measurement scales greatly improves the symptom 
assessment process, it may help direct treatment choices, and it provides 
information about the effectiveness of interventions (Cleeland 2000). Fatigue 
assessment can be linked to evidence-based or best practice guidelines to 
expedite optimal treatment. The results obtained in this thesis, combined with 
findings reported in the literature, show that CRF is a symptom influenced by 
multiple factors comprising both biological and psychosocial domains. When 
evaluating CRF, the health-care professionals therefore need to include both 
subjective and objective data.
Portenoy and Itri (1999) suggest the routine use of three questions to help 
assess the severity of fatigue and its impact over time:
1. Are you experiencing any fatigue?
2. If so, how severe has it been, on average, during the past week?
If fatigue is present it is possible to use a simple 0 to 10 numeric rating scale 
where mild fatigue may be indicated as a score 0-3, moderate fatigue as 4 to 6, 
and severe fatigue as 7 to 10.
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3. How does the fatigue interfere with your ability to function?
These three questions give the nurse some knowledge of the patient’s status. 
This information may also indicate whether there is need for further 
investigation and serves as a baseline for future follow-up of the patient’s 
experience of CRF. The 0 to 10 numeric rating scale however only provides a 
uni dimensional assessment of the multidimensional concept fatigue. Other 
characteristics are similarly important, for example, onset, duration, severity, 
daily pattern, time course, exacerbating and reducing factors, and distress 
associated with fatigue (Ahlberg et al 2003).
Nurses and other health-care professionals need to identify cancer patients at 
risk for poor adjustment during the period illness and/or treatment. 
Pretreatment screening for fatigue and its influencing variables is needed to 
identify patients at risk for developing the symptom. In the United States, the 
National Comprehensive Cancer Network (NCCN) proposed in their Fatigue 
Practice Guidelines an algorithm in which patients are assessed regularly for 
fatigue using a brief screening instrument (Mock et al 2000). The algorithm 
included the following phases: screening, primary evaluation, intervention and 
re-evaluation. The screening for the presence and severity of CRF should occur 
at the patient’s initial contact with an oncology provider, at appropriate 
intervals, and as clinically indicated. If fatigue is reported during screening, it 
should be quantified for future comparison. Data from a comprehensive 
assessment may suggest plausible hypotheses concerning pathogenesis, which 
in turn may suggest appropriate strategies. The guideline provides an overall 
framework for clinical practice but no outcomes research has been conducted to 
determine the effectiveness of the guideline on fatigue in cancer populations 
(Ahlberg et al 2003).
When measuring CRF there are several factors that should be considered. 
Because CRF fluctuates in severity over time it must be measured as a state 
rather than as a stable characteristic. Since CRF changes over time, evaluations 
of the experience of fatigue must be done repeatedly in relation to the disease, 
the therapy, the patient’s situation, and treatment of CRF and other symptoms. 
Also potential confounding exists in the measurement of CRF because of its 
close association with other concepts linked to fatigue, e.g. depression. 
Furthermore, instrument reactivity is a critical issue with CRF, because 
respondent burden can induce the condition (Meek et al 2000)
Ream and Richardson (1999) contend that passive approaches frequently fail to 
reduce fatigue in patients with cancer. Instead, alternative approaches based on 
the growing body of theoretical and research evidence should be adopted. 
Patients require guidance in managing cancer-related fatigue, and nurses 
therefore need to develop and evaluate relief interventions, e.g. educational, 
attention-restoring, and psychosocial interventions (Ream & Richardson 1999). 
All of the interventions proposed in the literature for managing CRF are health 
policy challenges because they represent additions to usual care rather than 
changing existing components of care (Nail 2002). Wengström and Forsberg 
(1999) stated after reviewing the literature that since patients receiving
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radiation therapy often experience side effects and complications as a result of 
treatment, they need information about their treatment, general emotional 
support, and practical help with side effects. The first step in treating a cancer 
patient’s fatigue may be to determine the patient’s expectations and to set 
realistic goals (Berger 2003). The uncertainty regarding what to expect with a 
cancer diagnosis and the occurrence of side-effects such as fatigue from 
radiotherapy makes it difficult for patients to predict what it is going to be like 
or how they are going to feel (Wells 1998). This necessitates discussion with 
emphasis on the individual patient’s experience.
Acknowledging fatigue as a common symptom in cancer patients receiving 
radiotherapy is important and may be the next step in management. Patients 
must be taught that fatigue is an expected effect of radiation treatment and that 
fatigue may be increased as a result of other influencing factors. Educating 
patients about CRT also includes helping them choose the most appropriate 
interventions for fighting fatigue. Efforts to manage fatigue in cancer patients 
should focus on correcting potential aetiologies and relieving symptoms (Mock 
et al 2003).
Guidelines for how to assess and manage symptoms and their outcomes need to 
be formulated. As earlier mentioned, the NCCN Fatigue Practice Guidelines 
Panel has reviewed the available evidence on CRF and the consensus of 
practitioners regarding the management of fatigue, and has developed clinical 
practice guidelines that are ready to use (Mock 2001), although further research 
is needed to support the use of the guidelines in clinical practice. Establishing 
special nursing care units within an oncology department, with sufficient time 
for nursing assessment, nursing interventions, and evaluation of symptoms and 
patient outcomes, and inclusion of these units in the overall treatment strategies 
of a multidisciplinary team, may be one way to offer better care to cancer 
patients suffering from CRF and other symptoms. Collaboration with other 
professionals is important as evaluation and treatment of CRF requires a 
multidisciplinary approach because of the multitude of possible aetiologies and 
contributing factors.
FURTHER RESEARCH
Although we were able to contribute new knowledge related to fatigue in 
patients with uterine cancer, there are some important gaps in our knowledge 
regarding the experience, mechanisms and management of CRF. Current 
studies of cancer-related fatigue interventions have focused predominately on 
breast cancer patients. Theories underlying the interventions being tested have 
not always been clearly explained, and thus our understanding of mediating 
mechanisms of CRF is insufficient. Study designs have been limited due to the 
lack of control groups and small sample sizes among other factors. Little 
research has been conducted on patients with advanced disease or patients who 
are elderly. These patients present obvious challenges as research subjects, as 
they are often more debilitated and have many co-morbidities and life demands
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that make participation in research difficult, and that often confound findings 
(Ahlberg et al 2003).
Implications for future research include a follow-up study of the present data in 
studies II-IV after 3, 6, 9 and 12 months.
There is also a need for:
• Further investigations regarding the mechanisms underlying the 
development of fatigue
• Intervention-testing research including nursing interventions that may 
reduce CRF
• Intervention-testing research including nursing interventions that may 
reduce other symptoms (e.g. GI symptoms; anorexia, nausea/vomiting, 
diarrhoea) that are related to CRF
• Qualitative research with the aim to to understand what cancer-related 
fatigue means to the patient, the place it occupies in his/her life and how 
he/she interprets and relates to fatigue.
• Investigations concerning the occurrence of a response shift in CRF and 
health-related quality of life ratings over time and the implications for 
the outcomes and estimation of the effectiveness of interventions
• Investigations concerning the relationship between the experience of 
CRF, health-related quality of life and symptom distress
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POPULÄRVETENSKAPLIG SAMMANFATTNING
Cancer-relaterad trötthet - upplevelse och konsekvenser
Bakgrund
Trötthet anses i dag som det mest frekvent rapporterade symtomet i samband 
med cancersjukdom. Symtomet förekommer över ett kontinuum som spänner 
från trötthet till utmattning. Det sista kan ses som ett tillstånd när man till 
och med vaknar utmattad efter en natts sömn. Studier visar att trötthet ofta 
upplevs som det mest besvärande symtomet. Olika faktorer har relaterats till 
trötthet i samband med cancersjukdom, t ex cancersjukdomen i sig, 
cancerbehandlingen samt andra symtom som till exempel smärta, oro, 
depression och anemi. Det saknas fortfarande kunskap om upplevelsen av 
trötthet över tid samt riskfaktorer för att utveckla trötthet hos patienter med 
cancersjukdom.
Syfte
Syftet med avhandlingen var att utveckla befintlig kunskap om cancerrelaterad 
trötthet genom att beskriva upplevelsen av trötthet, utvecklingen av trötthet 
över tid och relationen mellan trötthet och hälsorelaterad livskvalitet hos 
patienter med livmodercancer som får strålbehandling. Vidare att studera 
relationen mellan trötthet och andra symptom (smärta, illamående/kräkningar, 
aptitlöshet, diarré, sömnlöshet) liksom relationen mellan trötthet och 
fysiologiska mekanismer (anemi, frisättning av inflammatoriska ämnen som 
IL-1, IL-6, TNF-alfa) samt att identifiera riskfaktorer for utveckling av trötthet. 
Resultatet skall leda till en ökad förståelse samt ligga till grand för åtgärder för 
att förebygga eller minska cancerrelaterad trötthet.
Metod
Både kvalitativ och kvantitativ metod har använts. I den kvalitativa studien 
intervjuades 15 personer med cancersjukdom och analyserades med en 
kvalitativ metodik, Grounded Theory. I de kvantitativa studierna 
inkluderades 60 patienter med livmoderscancer som var planerade för 
strålbehandling. Data insamlades före, under samt efter avslutad behandling 
genom självskattningsinstrament och analyserades genom beskrivande och 
korrelerande statistiska metoder.
Resultat
Resultatet i den kvalitativa studien visade att tröttheten upplevdes som ett 
komplext fenomen med påverkan på bland annat vardaglig funktion och 
känslan av kontroll. Man beskrev till exempel en upplevelse av brist på 
energi, ett ökat behov av vila, en sjukdomskänsla, ett psykologiskt obehag, 
en känslomässig påverkan, en tyngdkänsla i kroppen, en onormal svaghet, 
svårigheter att tänka klart och att koncentrera sig samt svårigheter att ta 
initiativ. Upplevelsen ledde i sin tur till en social begränsning, påverkad 
självkänsla, en känsla av värdelöshet samt nedsatt livskvalitet.
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Respondenterna försökte att på olika sätt hantera sin upplevelse av trötthet 
bland annat genom egenvårdsåtgärder såsom till exempel att vila extra eller 
att försöka tänka på annat.
Resultatet från de kvantitativa studierna visade att patienterna hade en lätt grad 
av trötthet före start av strålbehandling. Graden av trötthet ökade signifikant 
under pågående behandling och efter avslutad behandling. Under pågående 
behandling och efter avslutad behandling upplevde 77-89 % av inkluderade 
patienter någon grad av trötthet. Graden av andra symtom såsom aptitlöshet, 
illamående/kräkningar, diarré och smärta ökade också under pågående 
behandling, ökningen var signifikant korrelerad till graden av generell trötthet. 
Patienterna upplevde en lätt grad av psykologiska symtom såsom oro och 
depression före start av behandling. Även om graden av depression hade 
tilltagit efter avslutad strålbehandling låg värdena fortfarande inom gränsen för 
normalt tillstånd. Patienternas förmåga till hantering av sin situation, i 
avhandlingen definierat som känsla av sammanhang, var stabil genom hela 
undersökningen. Graden av hälsorelaterad livskvalitet var hög före start av 
behandling. En nedsättning uppmättes för skattningen av global livskvalitet 
samt social funktion över tid. Det fanns en signifikant relation mellan 
skattningen av ökad generell trötthet och nedsättningen av global livskvalitet 
före start av behandling, efter tre veckors behandling samt efter avslutad 
behandling. Det fanns också en signifikant korrelation mellan ökningen av 
generell trötthet och nedsättningen av fysisk funktion, rollfunktion samt 
kognitiv funktion.
Patienternas hemoglobinvärde minskade signifikant under pågående 
behandling, dock kvarstod de inom normala gränsvärden. Det fanns ingen 
signifikant kon-elation mellan utvecklingen av generell trötthet och IL-I, TNF- 
alfa och hemoglobin. Det fanns en signifikant negativ korrelation mellan 
förändringen i IL-6 och generell trötthet. Variationen i graden av trötthet efter 
avslutad strålbehandling kunde i huvudsak förklaras av graden av generell 
trötthet före start av behandling.
Diskussion
Avhandlingen belyser ett symtom, cancer-relaterad trötthet, som har stor 
betydelse för patienter med cancersjukdom och studerar denna i en specifik 
population. Den kliniska relevansen är att resultatet kan förbättra 
omhändertagandet och omvårdnaden av patienter med livmodercancer som 
behandlas med strålbehandling. Avhandlingens resultat bekräftar befintlig 
kunskap samt ger ny kunskap genom beskrivningen av trötthet, påverkande 
faktorer och konsekvenser över tid. Trots att cancerrelaterad trötthet är ett 
vanligt förekommande symtom är det sällsynt att tröttheten systematiskt 
undersöks, behandlas eller utvärderas. Orsakerna till det är relaterat till flera 
faktorer, bland annat brist på förståelse för de mekanismer som orsakar 
tröttheten, brist på medvetenhet hos vårdpersonalen samt brist på 
evidensbaserade åtgärder. Sjuksköterskor har en viktig roll när det gäller att 
upprätthålla och förbättra hälsorelaterad livskvalitet hos patienter med risk att 
utveckla cancerrelaterad trötthet. Patienter bör informeras om risken för
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utveckling av cancerrelaterad trötthet över tid. Åtgärder för att minska 
cancerrelaterad trötthet skall baseras pâ en undersökning om dels graden av 
trötthet samt dels vilken påverkan tröttheten har på patienten. Upplevelsen av 
trötthet skall skattas av patienten själv. Resultatet i denna avhandling 
tillsammans med litteraturen visar att cancerrelaterad trötthet är ett symtom 
som kan påverkas av flera faktorer. Därför bör framtida undersökningar 
inkludera både subjektiva och objektiva data. För optimal undersökning, 
behandling och utvärdering av cancerrelaterad trötthet är ett multidisciplinärt 
förhållningssätt, på grund av antalet möjliga orsaker till uppkommen trötthet, 
att rekommendera.
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